<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2804245222
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KADCYLA 160 mg powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TRASTUZUMAB EMTANSINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        160
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        8761.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Manufacturing Services LLC " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Manufacturing Services LLC 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ROCHE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Kadcyla contains the active substance trastuzumab emtansine, which is made up of two parts that are linked together:</strong></p><p dir="ltr"><strong>∙ trastuzumab - a monoclonal antibody that binds selectively to an antigen (a target protein) called human epidermal growth factor receptor 2 (HER2). HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. When trastuzumab binds to HER2 it can stop the cancer cells growth and cause them to die.</strong></p><p dir="ltr"><strong>∙ DM1 &ndash; an anti-cancer substance that becomes active once Kadcyla enters the cancer cell.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>What Kadcyla is used for</strong></p><p dir="ltr"><strong>Kadcyla is used to treat breast cancer in adults when:</strong></p><p dir="ltr"><strong>∙ the cancer cells have many HER2 proteins on them - your doctor will test your cancer cells for this.</strong></p><p dir="ltr"><strong>∙ the cancer has spread to areas near the breast or to other parts of your body (metastasised)</strong></p><p dir="ltr"><strong>∙ you have already received the medicine trastuzumab and a medicine known as a taxane.</strong></p><p dir="ltr"><strong>∙ the cancer has not spread to other parts of the body and treatment is going to be given after surgery (treatment after surgery is called adjuvant therapy) for patients who still have a residual invasive disease&nbsp; despite being treated by other neoadjuvant anti-cancer medications (taxane and trastuzumab -based treatment (treatment before surgery is called neoadjuvant therapy).&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>You must not be given Kadcyla</strong></p><p dir="ltr"><strong>∙ if you are allergic to trastuzumab emtansine or any of the other ingredients of this medicine (listed in section 6).&nbsp;</strong></p><p dir="ltr"><strong>You should not be given Kadcyla if the above applies to you. If you are not sure, talk to your doctor or nurse before you are given Kadcyla.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Warnings and precautions</strong></p><p dir="ltr"><strong>Talk to your doctor or nurse before you are given Kadcyla if:</strong></p><p dir="ltr"><strong>∙ you have ever had a serious infusion-related reaction from using trastuzumab characterised by symptoms such as flushing, chills, fever, shortness of breath, difficulty breathing, rapid heartbeat or a drop in blood pressure.</strong></p><p dir="ltr"><strong>∙ you are receiving treatment with blood thinning medicines (e.g. warfarin, heparin).</strong></p><p dir="ltr"><strong>∙ you have any history of&nbsp; liver problems. Your doctor will check your blood to test your liver function before and regularly during treatment</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before you are given Kadcyla.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Look out for side effects</strong></p><p dir="ltr"><strong>Kadcyla can make some existing conditions worse, or cause side effects. See section&nbsp;4 for more details about what side effects to look out for.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tell your doctor or nurse straight away if you notice any of the following serious side effects while you are given Kadcyla:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Breathing problems: Kadcyla can cause serious breathing problems such as shortness of breath (either at rest or while performing any type of activity) and cough.&nbsp; These may be signs of inflammation of your lung, which may be serious, and even fatal. If you develop lung disease your doctor may stop treatment with this medicine.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Liver problems: Kadcyla can cause inflammation or damage to cells in the liver that can stop the liver from functioning normally. Inflamed or injured liver cells may leak higher than normal amounts of certain substances (liver enzymes) into the bloodstream, resulting in elevated liver enzymes in blood tests. In most cases you will not have any symptoms. Some symptoms could be yellowing of your skin and whites of your eyes (jaundice). Your doctor will check your blood to test your liver function before and regularly during treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Another rare abnormality that can occur in the liver is a condition known as nodular regenerative hyperplasia (NRH). This abnormality causes the structure of the liver to change and can change how the liver functions. Over time, this may lead to symptoms such as a bloated sensation or swelling of the abdomen due to fluid accumulation or bleeding from abnormal blood vessels in the gullet or rectum.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Heart problems: Kadcyla can weaken the heart muscle. When the heart muscle is weak, patients may develop symptoms such as shortness of breath at rest or when sleeping, chest pain, swollen legs or arms, and a sensation of rapid or irregular heartbeats. Your doctor will check your heart function before and regularly during treatment. You should tell your doctor immediately if you notice any of the above symptoms.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Infusion-related reactions or allergic reactions: Kadcyla can cause flushing, shivering fits, fever, trouble breathing, low blood pressure, rapid heartbeat, sudden swelling of your face, tongue, or trouble swallowing during the infusion or after the infusion on the first day of treatment. Your doctor or nurse will check to see whether you are having any of these side effects. If you develop a reaction, they will slow down or stop the infusion and may give you treatment to counteract the side effects. The infusion may be continued after the symptoms improve.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Bleeding problems: Kadcyla can lower the number of platelets in your blood. Platelets help your blood to clot so you might get unexpected bruising or bleeding (such as nose bleeds, bleeding from gums). Your doctor will check your blood regularly for decreased platelets. You should tell your doctor immediately if you notice any unexpected bruising or bleeding.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Neurological problems: Kadcyla can damage nerves. You may experience tingling, pain, numbness, itching, crawling sensation, pins and needles in your hands and feet. Your doctor will monitor you for signs and symptoms of neurological problems.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tell your doctor or nurse straight away if you notice any of the side effects above.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Children and adolescents</strong></p><p dir="ltr"><strong>Kadcyla is not recommended for anyone under the age of 18&nbsp;years. This is because there is no information on how well it works in this age group.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Other medicines and Kadcyla</strong></p><p dir="ltr"><strong>Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In particular, tell your doctor or pharmacist if you are taking:</strong></p><p dir="ltr"><strong>∙ any medicines to thin your blood such as warfarin or decrease the ability to form blood clot such as aspirin</strong></p><p dir="ltr"><strong>∙ medicines for fungal infections called ketoconazole, itraconazole or voriconazole</strong></p><p dir="ltr"><strong>∙ antibiotics for infections called clarithromycin or telithromycin</strong></p><p dir="ltr"><strong>∙ medicines for HIV called atazanavir, indinavir, nelfinavir, ritonavir or saquinavir.</strong></p><p dir="ltr"><strong>∙ medicine for depression called nefazodone</strong></p><p dir="ltr"><strong>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before you are given Kadcyla.&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy</strong></p><p dir="ltr"><strong>Kadcyla is not recommended if you are pregnant because this medicine may cause harm to the unborn baby.&nbsp;</strong></p><p dir="ltr"><strong>∙ Tell your doctor before using Kadcyla if you are pregnant, think you may be pregnant or are planning to have a baby.</strong></p><p dir="ltr"><strong>∙ Use effective contraception to avoid becoming pregnant while you are being treated with Kadcyla.. Talk to your doctor about the best contraception for you.</strong></p><p dir="ltr"><strong>∙ You should continue to take your contraception for at least 7 months after your last dose of Kadcyla. Talk to your doctor before stopping your contraception.&nbsp;</strong></p><p dir="ltr"><strong>∙ Male patients or their female partners should also use effective contraception.&nbsp;</strong></p><p dir="ltr"><strong>∙ If you do become pregnant during treatment with Kadcyla, tell your doctor straight away.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Breast-feeding</strong></p><p dir="ltr"><strong>You should not breast-feed during treatment with Kadcyla. Also you should not breast-feed for&nbsp;7 months after your last infusion of Kadcyla. It is not known whether the ingredients in Kadcyla pass into breast-milk. Talk to your doctor about this.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr"><strong>It is not expected that Kadcyla will affect your ability to drive, cycle, use tools or machines. If you experience flushing, shivering fits, fever, trouble breathing, low blood pressure or a rapid heartbeat (infusion-related reaction), blurred vision, tiredness, headache, or dizziness, do not drive, cycle, use tools or machines until these reactions stop.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Important information about some of the ingredients of Kadcyla</strong></p><p dir="ltr"><strong>This medicine contains less than 1 mmol sodium (23 mg) per dose. It is essentially &lsquo;sodium- free&rsquo;.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Kadcyla will be given to you by a doctor or nurse in a hospital or clinic:</strong></p><p dir="ltr"><strong>∙ It is given by a drip into a vein (intravenous infusion).</strong></p><p dir="ltr"><strong>∙ You will be given one infusion every&nbsp;3&nbsp;weeks.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>How much you will be given</strong></p><p dir="ltr"><strong>∙ You will be given 3.6&nbsp;mg of Kadcyla for every kilogram of your body weight. Your doctor will calculate the correct dose for you.</strong></p><p dir="ltr"><strong>∙ The first infusion will be given to you over 90&nbsp;minutes. You will be observed by a doctor or nurse while it is being given and for at least 90&nbsp;minutes following the initial dose, in case you have any side effects.&nbsp;</strong></p><p dir="ltr"><strong>∙ If the first infusion is well tolerated, the infusion on your next visit may be given over 30&nbsp;minutes. You will be observed by a doctor or nurse while it is being given and for at least 30&nbsp;minutes following the dose, in case you have any side effects.</strong></p><p dir="ltr"><strong>∙ The number of infusions you will be given depends on how you respond to treatment and type of cancer (if the disease has spread or not).</strong></p><p dir="ltr"><strong>∙ If you experience side effects, your doctor may decide to continue your treatment but lower your dose, delay the next dose or stop the treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you miss a Kadcyla treatment</strong></p><p dir="ltr"><strong>If you forget or miss your Kadcyla appointment, make another appointment as soon as possible. Do not wait until your next planned visit.&nbsp;</strong></p><p><br />&nbsp;</p><p dir="ltr"><strong>If you stop Kadcyla treatment</strong></p><p dir="ltr"><strong>Do not stop treatment with this medicine without talking to your doctor first.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you have any further questions on the use of this medicine, ask your doctor or nurse.&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Like all medicines, this medicine can cause side effects, although not everybody gets them.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tell your doctor or nurse straight away if you notice any of following serious side effects.</strong></p><p dir="ltr"><strong>Very common (may affect more than 1 in 10 people):</strong></p><p dir="ltr"><strong>∙ Kadcyla may cause inflammation or damage to cells in the liver, resulting in elevated liver enzymes in blood tests. However, in most cases during Kadcyla treatment, liver enzyme levels are elevated mildly and temporarily, do not cause any symptoms, and do not affect liver function.</strong></p><p dir="ltr"><strong>∙ Unexpected bruising and bleeding (such as nose bleeds).</strong></p><p dir="ltr"><strong>∙ Tingling, pain, numbness, itching, crawling sensation, pins and needles in your hands and feet. These symptoms may indicate nerve damage.</strong></p><p dir="ltr"><strong>Common (may affect up to 1 in 10 people):</strong></p><p dir="ltr"><strong>∙ Flushing, shivering fits, fever, trouble breathing, low blood pressure or a rapid heartbeat during the infusion or up to 24 hours after the infusion &ndash; these are so-called infusion-related reactions.&nbsp;</strong></p><p dir="ltr"><strong>∙ Heart problems can occur. Most patients will not have symptoms from the heart problems. If symptoms do occur, cough shortness of breath at rest or when sleeping flat, chest pain and swollen ankles or arms, a sensation of rapid or irregular heartbeats may be observed.&nbsp;</strong></p><p dir="ltr"><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><p dir="ltr"><strong>∙ Inflammation of your lungs can cause breathing problems such as shortness of breath (either at rest or while performing any type of activity), coughing or coughing spells with a dry cough &ndash; these are signs of inflammation of your lung tissue.</strong></p><p dir="ltr"><strong>∙ Your skin and whites of your eyes get yellow (jaundice) &ndash; these could be signs of severe liver damage.</strong></p><p dir="ltr"><strong>∙ Allergic reactions can occur and most patients will have mild symptoms such as itching or tightness in the chest. In more severe cases, swelling of your face or tongue, trouble swallowing or difficulty breathing may occur.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tell your doctor or nurse straight away if you notice any of the serious side effects above.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Other side effects include</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Very common:</strong></p><p dir="ltr"><strong>∙ decreased red blood cells (shown in a blood test)</strong></p><p dir="ltr"><strong>∙ being sick (vomiting)</strong></p><p dir="ltr"><strong>∙ diarrhoea&nbsp;</strong></p><p dir="ltr"><strong>∙ dry mouth</strong></p><p dir="ltr"><strong>∙ urinary tract infection</strong></p><p dir="ltr"><strong>∙ constipation</strong></p><p dir="ltr"><strong>∙ stomach ache</strong></p><p dir="ltr"><strong>∙ cough</strong></p><p dir="ltr"><strong>∙ shortness of breath</strong></p><p dir="ltr"><strong>∙ inflammation of the mouth</strong></p><p dir="ltr"><strong>∙ chills or flu like symptoms</strong></p><p dir="ltr"><strong>∙ decrease in your potassium levels (shown in a blood test)</strong></p><p dir="ltr"><strong>∙ difficulty sleeping</strong></p><p dir="ltr"><strong>∙ muscle or joint pain</strong></p><p dir="ltr"><strong>∙ fever</strong></p><p dir="ltr"><strong>∙ headache</strong></p><p dir="ltr"><strong>∙ skin rashes</strong></p><p dir="ltr"><strong>∙ feeling tired</strong></p><p dir="ltr"><strong>∙ weakness</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Common:</strong></p><p dir="ltr"><strong>∙ decreased white blood cells (shown in a blood test)</strong></p><p dir="ltr"><strong>∙ dry eyes, watery eyes or blurred vision</strong></p><p dir="ltr"><strong>∙ eye redness or infection</strong></p><p dir="ltr"><strong>∙ indigestion</strong></p><p dir="ltr"><strong>∙ swelling of legs and/or arms</strong></p><p dir="ltr"><strong>∙ bleeding from the gums</strong></p><p dir="ltr"><strong>∙ increase in blood pressure&nbsp;</strong></p><p dir="ltr"><strong>∙ feeling dizzy</strong></p><p dir="ltr"><strong>∙ taste disturbances</strong></p><p dir="ltr"><strong>∙ itching</strong></p><p dir="ltr"><strong>∙ difficulty in remembering</strong></p><p dir="ltr"><strong>∙ hair loss</strong></p><p dir="ltr"><strong>∙ hand-and-foot skin reaction (Palmar-plantar erythrodysaesthesia syndrome)</strong></p><p dir="ltr"><strong>∙ nail disorder</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Uncommon:</strong></p><p dir="ltr"><strong>∙ Another abnormality that can be caused by Kadcyla is a condition known as nodular regenerative hyperplasia of the liver. This abnormality causes the structure of the liver to change. Patients develop multiple nodules in the liver that can change how the liver functions. Over time, this may lead to symptoms such as a bloated sensation or swelling of the abdomen due to fluid accumulation or bleeding from abnormal blood vessels in the gullet or rectum.</strong></p><p dir="ltr"><strong>∙ If the Kadcyla infusion solution leaks into the area around the infusion site you may develop tenderness or redness of your skin, or swelling at the infusion site.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you get any of the side effects after your treatment with Kadcyla has stopped, talk to your doctor or nurse and tell them that you have been treated with Kadcyla.</strong></p><p><br /><br />&nbsp;</p><p dir="ltr"><strong>Reporting of side effects</strong></p><p dir="ltr"><strong>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>By reporting side effects you can help provide more information on the safety of this medicine.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Kadcyla will be stored by the health professionals at the hospital or clinic.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ Keep this medicine out of the sight and reach of children.</strong></p><p dir="ltr"><strong>∙ Do not use this medicine after the expiry date which is stated on the outer carton after EXP. The expiry date refers to the last day of that month.</strong></p><p dir="ltr"><strong>∙ Store in a refrigerator at (2&deg;C&nbsp; 8&deg;C). Do not freeze.</strong></p><p dir="ltr"><strong>∙ When prepared as a solution for infusion Kadcyla is stable for up to 24 hours at 2&deg;C&nbsp;to&nbsp;8&deg;C, and must be discarded thereafter.&nbsp;</strong></p><p dir="ltr"><strong>∙ Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help to protect the environment.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What Kadcyla contains</strong></p><p dir="ltr"><strong>∙ The active substance is trastuzumab emtansine.&nbsp;</strong></p><p dir="ltr"><strong>∙ Each 100 mg single-use vial containing powder for concentrate for infusion solution designed to deliver 5 ml of 20 mg/ml of trastuzumab emtansine.&nbsp;</strong></p><p dir="ltr"><strong>∙ Each 160 mg single-use vial containing powder for concentrate for infusion solution designed to deliver 8 ml of 20 mg/ml of trastuzumab emtansine.&nbsp;</strong></p><p dir="ltr"><strong>∙ The other ingredients are succinic acid, sodium hydroxide (see section 2 under &lsquo;Important information about some of the ingredients of Kadcyla&rsquo;), sucrose, and polysorbate&nbsp;20.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Kadcyla is a white to off-white lyophilised powder for concentrate for solution for infusion supplied in glass vials. 
∙	Kadcyla is available in packs containing 1 vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>F. Hoffmann-La Roche Ltd,</strong></p><p dir="ltr"><strong>Grenzacherstrasse 124,&nbsp;</strong></p><p dir="ltr"><strong>CH-4070 Basel,&nbsp;</strong></p><p dir="ltr"><strong>Switzerland.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in May 2019.

To report any side effect(s):
Saudi Arabia:
The National Pharmacovigilance and Drug Safety Centre (NPC)
Fax: +966-11-205-7662
Call NPC at +966-11-2038222, Exts: 2317-2356-2340.
SFDA call center: 19999 
E-mail: npc.drug@sfda.gov.sa
Website: www.sfda.gov.sa/npc

Other GCC States:
Please contact the relevant competent authority.

Council of Arab Health Ministers:
This is a Medicament
Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you. 
Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament. 
The doctor and the pharmacist are the experts in medicines, their benefits and risks. 
Do not by yourself interrupt the period of treatment prescribed for you. 
Do not repeat the same prescription without consulting your doctor. 
Keep all medicaments out of reach of children. 
Council of Arab Health Ministers
Union of Arab Pharmacists




            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>كادسيال يحتوي على المادة الفعالة تراستوزوماب إمتانسين، التي تتكون من جزئين مرتبطين معا  تراستوزوماب &ndash; وهو جسم مضاد أحادي النسيلة يلتصق بشكل انتقاائي بمستضاد )باروتين مساتهدفي يسامى مساتقبل عامل النمو الجلدي البشري 2( HER2ي. يوجد HER2 بكميات كبيرة على ساطح بعاا الخالياا السارطانية حياث يحفز نموها. عندما يلتصق تراستوزوماب بخاليا HER2 السرطانية فقد يوقف نموها، و يؤدي إلى موتها.  مادة دي إم 1 المقاومة للسرطان التي تصبح نشطة بمجرد أن يدخل كادسيال إلى الخلية السرطانية.</p><p>ما هو الغرض من استخدام كادسيال؟ يستخدم كادسيال في عالج سرطان الثدي عند الكبار عندما:  تحتوي الخاليا السرطانية على العديد من بروتينات عامال النماو الجلادي البشاري 2( HER2ي &ndash; سيفحصاك طبيباك الكتشاف ذلك.  يكون السرطان قد انتشر إلى األجزاء من الجسم القريبة من الثدي أو أجزاء الجسم األخرى.  سبق وأن تم تلقي العالج باستخدام الدواء تراستوزوماب ودواء اسمه تاكسان.  يكون السرطان لم ينتشر ألجزاء أخرى من الجسم وسايتم إعطااء العاالج بعاد الجراحاة )يسامى العاالج بعاد الجراحاة للمرضاى الاذين تلقاوا عالجاا التراساتوزوماب قبال بالعالج المسااعدي بأدوياة مضاادة للسارطان باساتخدام التاكساان و خضاوعهم للجراحاة )يسامى العاالج قباال الجراحااة باالعالج المباادئي المساااعدي و تبقااى لااديهم بعاا الخالياا القابلااة لالنتشار</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب عليك عدم أخذ دواء كادسيال في الحاالت التالية:  إذا كانت لديك حساسية لمادة تراستوزوماب إمتانسين أو أي من المكونات األخرى لهذا الدواء )المذكورة في الجزء السادسي. حيث يجب عليك عدم تناول كادسيال إذا كان لديك حساسية. فإذا كنت غير متأكد، تحدث إلى طبيبك أو ممرضتك قبل تناول كادسيال. التحذيرات واالحتياطات: تحدث إلى طبيبك أو ممرضتك قبل تناول كادسيال في الحاالت التالية:  سبق وأن تعرضت ألي ردود فعل تحسسية شديدة أثناء الحقن الوريدي نتيجة استخدام تراستوزوماب والتي تتمثل في بعا األعراا مثل االحمرار أو القشعريرة أو الحمى أو قصر التنفس أو صعوبة التنفس أو سرعة ضربات القلب أو انخفاا في ضغط الدم.  إذا كنت تتلقى العالج بأدوية مسيلة للدم )مثل وارفارين وهيباريني.  إذا كان لديك أي تاريخ مرضي سابق لمشكالت في الكبد. سيقوم طبيبك بإجراء فحص الدم الختبار وظائف الكبد قبل وأثناء العالج بشكل منتظم. ا إن لم تك ي، تحدث فإذا كان ينطبق عليك أي مما سبق )أو ن متأكدا إلى طبيبك أو الصيدلي قبل تناول كادسيال. اآلثار الجانبية: من الممكن أن يتسبب كادسيال في تفاقم بعا الحاالت أو حدوث بعا اآلثار الجانبية. انظر الجزء الرابع للمزيد من التفاصيل عن ما هي اآلثار الجانبية التي يتعين عليك مالحظتها ومتابعتها. أخبر طبيبك أو ممرضتك مباشرة في حالة مالحظتك أي من اآلثار الجانبية الخطيرة التالية أثناء تناول كادسيال:  مشكالت التنفس: من الممكن أن يتسبب كادسيال في حدوث مشكالت تنفسية خطيرة مثل قصر التنفس )سواء في وقت الراحة أو أثناء أداء أي نوع من األنشطةي والكحة. وقد تكون هذه األعراا مؤشرات على حدوث التهاب في الرئة، وقد يكون هذا االلتهاب خطيرا، وقد يؤدي إلى الوفاة. وفي حالة حدوث أمراا الرئة، قد يقرر طبيبك إيقاف العالج بهذا الدواء.  مشكالت الكبد: من الممكن أن يتسبب كادسيال في حدوث التهاب أو تلف في خاليا الكبد والذي قد يؤدي إلى توقف الكبد عن العمل بشكل طبيعي. فخاليا الكبد الملتهبة أو المصابة قد يحدث بها تسريب بمعدل أكبر من الكميات الطبيعية لبعا المواد )مثل إنزيمات الكبدي في الدم، مما يترتب عليه ارتفاع إنزيمات الكبد في اختبارات الدم. وفي معظم الحاالت لن يحدث لديك أي أعراا. وبعا األعراا قد تشمل اصفرار في الجلد وبياا العين )مرا الصفراءي. وسوف يقوم طبيبك بعمل اختبارات الدم للتأكد من وظائف الكبد قبل وأثناء العالج بصورة منتظمة. ويعتبر تضخم الكبد إحدى الحاالت األخرى التي يمكن أن تصيب الكبد وتغير من وظائفه. ومع مرور الوقت يؤدي ذلك إلى بعا األعراا مثل الشعور بالتضخم أو التورم في البطن بسبب تراكم السوائل أو نزيف األوعية الدموية بشكل غير طبيعي في المرىء أو المستقيم.  مشكالت القلب: من الممكن أن يسبب كادسيال في ضعف عضلة القلب، ويؤدي ذلك إلى حدوث أعراا مثل قصر التنفس في أوقات الراحة أو أثناء النوم مع ألم في الصدر انتفاخ في القدمين أو الذراعين وشعور بسرعة أو عدم انتظام ضربات القلب. وسوف يقوم طبيبك بفحص وظائف القلب قبل وأثناء العالج بشكل منتظم. ويجب عليك إخبار طبيبك على الفور إذا الحظت أي من األعراا السابقة.  ردود الفعل التحسسية المصاحبة للحقن الوريدي أو الحساسية المفرطة: من الممكن أن يسبب كادسيال حدوث احمرار أو نوبات ارتجاف أو حمى أو صعوبة في التنفس أو انخفاا ضغط الدم أو سرعة ضربات القلب أو تورم مفاجئ في الوجه أو اللسان أو صعوبة البلغ أثناء أو بعد تلقي المحلول في اليوم األول من العالج. وسوف يقوم 3 المملكة العربية السعودية &ndash; نشرة معلومات المريض CDS 8.0 / US مرجع طبيبك أو ممرضتك بفحصك للتأكد من حدوث أي من هذه اآلثار الجانبية. وفي حالة حدوث أي رد فعل تحسسي، قد يتم إبطاء المحلول أو إيقافه وإعطائك عالج للسيطرة على هذه اآلثار الجانبية. ويمكن معاودة االستمرار في المحلول بعد تحسن األعراا.  مشكالت النزيف: من الممكن أن يتسبب كادسيال في تقليل عدد الصفائح الدموية في الدم. فالصفائح الدموية هي التي تساعد على تخثر الدم ولذلك قد تحدث لك نوبات غير متوقعة من النزيف أو الكدمات )مثل نزيف األنف ونزيف اللثةي. وسوف يقوم طبيبك بفحصك بانتظام وعمل اختبارات الدم للكشف عن انخفاا عدد الصفائح الدموية. ويجب عليك إخبار طبيبك على الفور في حالة مالحظة أي نزيف أو كدمات غير متوقعة.  مشكالت األعصاب: من الممكن أن يتسبب كادسيال في تلف األعصاب. فقد تشعر بالتنميل أو األلم أو الحكة أو وخز اإلبر أو الدبابيس في اليدين والقدمين. وسوف يراقب طبيبك عالمات وأعراا مشكالت األعصاب. أخبر طبيبك على الفور إذا الحظت أي من اآلثار الجانبية المذكورة أعاله. األطفال والمراهقون: ال ينصح باستخدام كادسيال ألي شخص أقل من 18 عام حيث أنه ال توجد معلومات عن تأثير هذا الدواء على هذه الفئة العمرية. األدوية األخرى وكادسيال: قد تتناول مستقبال أي أدوية أخرى. أخبر طبيبك أو ممرضتك إذا كنت تتناول أو تناولت مؤخرا أو أخبر طبيبك أو الصيدلي إذا كنت تتناول أي من األدوية التالية على وجه التحديد:  أي أدوية تسبب سيولة الدم مثل وارفارين أو تقلل قدرة الدم على التخثر مثل أسبرين.  أدوية عالج عدوى الفطريات مثل كيتوكونازول أو إتراكونازول أو فوريكونازول.  المضادات الحيوية لعالج العدوى مثل كالريثرومايسين أو تليثرومايسين.  أدوية فيروس نقص المناعة البشرية مثل أتازانافير أو إندينافير أو نيلفينافير أو ريتونافير أو ساكوينافير.  أدوية عالج االكتئاب مثل نيفازودون. فإذا كان أي مما سبق ينطبق عليك )أو إذا كنت غير متأكدي، تحدث مع طبيبك أو الصيدلي قبل تناولك كادسيال. الحمل: ال ينصح بتناول كادسيال أثناء الحمل ألنه قد يسبب ضررا للجنين. أو تعتقدي أن ك سوف تصبحين حامال أو تخططي للحمل.  أخبري طبيبك قبل تناول كادسيال إذا كن ت حامال  استخدمي وسيلة منع حمل فعالة لتجنب حدوث الحمل أثناء العالج باستخدام كادسيال. تحدثي مع طبيبك عن أفضل وسيلة منع حمل مناسبة ل ك.  يجب علي ك االستمرار في استخدام وسيلة منع الحمل لمدة ال تقل عن سبعة أشهر بعد آخر جرعة من دواء كادسيال. تحدثي مع طبيبك قبل إيقاف وسيلة منع الحمل.  يجب على المرضى الذكور أيضا أو زوجاتهم استخدام وسيلة منع حمل فعالة.  أخبري طبيبك على الفور في حالة حدوث الحمل بالفعل أثناء العالج. 4 المملكة العربية السعودية &ndash; نشرة معلومات المريض CDS 8.0 / US مرجع اإلرضاع: يجب علي ك عدم إرضاع طفلك أثناء تناول العالج باستخدام كادسيال ولمدة سبعة أشهر بعد آخر جرعة من دواء كادسيال. فمن غير المعروف ما إذا كانت عناصر دواء كادسيال تنتقل إلى الطفل عن طريق حليب الثدي. تحدثي مع طبيبك عن هذا األمر. القيادة واستخدام اآلالت: من غير المتوقع أن يؤثر كادسيال في قدرتك على القيادة أو ركوب الدراجات أو استخدام األدوات أو اآلالت. فإذا شعرت بأحد األعراا مثل االحمرار أو نوبات االرتجاف أو الحمى أو صعوبة التنفس أو انخفاا ضغط الدم أو سرعة ضربات القلب )ردود الفعل التحسسية المتعلقة بالمحلولي أو الزغللة أو التعب أو الصداع أو الدوار، يجب عليك عدم القيادة أو ركوب الدراجات أو استخدام األدوات أو اآلالت لحين زوال هذه األعراا. معلومات هامة عن بعض العناصر المكونة لعقار كادسيال: هذا العقار يحتوي على الصوديوم بمعدل أقل من 1 ملليمول )23 ملغي في الجرعة. فهو بشكل أساسي عقار &quot;خالي من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يتم إعطاؤك كادسيال من قبل الطبيب أو الممرضة في المستشفى أو العيادة:  يتم إعطاؤك الدواء على صورة محلول وريدي.  يتم إعطاؤك المحلول كل ثالثة أسابيع. كمية الدواء التي سوف يتم إعطاؤها لك؟  سوف يتم إعطاؤك 6.3 ملغ من كادسيال لكل كيلوجرام من وزن جسمك. وسوف يقوم طبيبك بحساب الجرعة الصحيحة لك.  سوف يتم حقن أول محلول على مدار 90 دقيقة. وسوف يتم مالحظتك من قبل الطبيب أو الممرضة أثناء إعطاؤك المحلول ولمدة 90 دقيقة على األقل بعد الجرعة المبدئية تحسبا لظهور أية آثار جانبية.  في حالة تحملك للجرعة األولى من المحلول، يتم إعطاؤك المحلول في الزيارة التالية على مدار 30 دقيقة. وسوف يتم مالحظتك من قبل الطبيب أو الممرضة أثناء إعطاؤك المحلول ولمدة 30 دقيقة على األقل بعد انتهاء الحقن تحسبا لظهور أية آثار جانبية.  إجمالي عدد المحاليل التي سوف يتم إعطاؤها لك يعتمد على درجة استجابتك للعالج و نوع السرطان لديك )في حال كان قد انتشر أم الي.  في حالة ظهور أية آثار جانبية، فإن طبيبك هو الذي قد يقرر االستمرار في العالج مع تخفيا الجرعة أو تأخير الجرعة التالية أو إيقاف العالج. إذا نسيت تلقي جرعة من كادسيال: ا آخر في أسرع وقت ممكن. وال تنتظر في حالة نسيانك أو عدم حضورك في الموعد المحدد للجرعة، رتب موعد ا حتى الموعد المحدد للزيارة التالية.</p><p>إذا توقفت عن العالج باستخدام كادسيال: . ال توقف العالج دون التحدث مع طبيبك أوال في حالة وجود أي أسئلة أخرى عن استخدام هذا الدواء يجب عليك طرح هذه األسئلة على الطبيب أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كجميع األدوية ˓ يمكن أن يسبب هذا الدواء آثا را جانبية ولكن ليس بالضرورة أن تصيب جميع مستخدميه. أخبر طبيبك أو الممرضة على الفور إذا الحظت أي من اآلثار الجانبية الخطيرة التالية: آثار جانبية شائعة جدا )قد تحدث ألكثر من شخص من بين كل عشرة أشخاص(:  من الممكن أن يسبب عقار كادسيال التهاب أو تلف في خاليا الكبد، مما ينتج عنه ارتفاع في إنزيمات الكبد ويظهر ذلك في اختبارات الدم. ولكن في غالبية الحاالت أثناء العالج بعقار كادسيال، ترتفع مستويات إنزيمات الكبد بشكل طفيف ومؤقت غير مسببة ألي أعراا وغير مؤثرة على وظيفة الكبد.  الكدمات والنزيف غير المتوقع )مثل نزيف األنفي.  التنميل أو األلم أو الحكة أو وخز اإلبر أو الدبابيس في اليدين والقدمين. وهذه األعراا قد تدل على تلف في األعصاب. آثار جانبية شائعة )قد تحدث لشخص واحد من بين كل عشرة أشخاص(:  االحمرار أو القشعريرة أو الحمى أو قصر التنفس أو صعوبة التنفس أو سرعة ضربات القلب أو انخفاا في ضغط الدم، وهي ما يطلق عليها ردود الفعل التحسسية المتعلقة بالمحاليل.  قد تحدث مشكالت في القلب. وغالبية المرضى ال تحدث لديهم أعراا من مشكالت القلب، ولكن يظهر ذلك على شكل كحة أو قصر في التنفس في أوقات الراحة أو أثناء النوم أو ألم في الصدر أو تورم في الكاحل أو الذراعين أو شعور بسرعة أو عدم انتظام ضربات القلب. آثار جانبية غير شائعة )قد تؤثر في شخص واحد من بين كل مائة شخص(:  التهاب في الرئتين والذي يمكن أن يسبب مشكالت في التنفس مثل قصر التنفس )سواء في أوقات الراحة أو أثناء أداء أي نشاطي أو الكحة أو نوبات السعال مع الكحة الجافة، وهذه األعراا تدل على التهاب في نسيج الرئة.  اصفرار في الجلد وبياا العين )مرا الصفراءي، وقد تكون هذه عالمات على تلف حاد في الكبد.  قد تحدث ردود فعل تحسسية وغالبية المرضى سوف تحدث لديهم أعراا طفيفة مثل الحكة أو ضيق في الصدر. وقد يحدث في معظم الحاالت الحادة تورم في الوجه أو اللسان أو صعوبة البلع أو صعوبة التنفس. أخبر طبيبك أو الممرضة على الفور إذا الحظت أي من اآلثار الجانبية المذكورة أعاله. تشمل اآلثار الجانبية األخرى ما يلي: آثار جانبية شائعة جدا :  انخفاا كرات الدم الحمراء )ويظهر ذلك في اختبارات الدمي  القىء  اإلسهال</p><p> جفاف الفم  التهاب المسالك البولية  اإلمساك  آالم المعدة  الكحة  قصر التنفس  التهاب الفم  الرعشة أو أعراا شبيهة باألنفلونزا  انخفاا في مستويات البوتاسيوم )ويظهر ذلك في اختبارات الدمي  صعوبة في النوم  ألم في العضالت أو المفاصل  الحمى  الصداع  الطفح الجلدي  الشعور بالتعب  الضعف العام آثار جانبية شائعة:  انخفاا كرات الدم البيضاء )ويظهر ذلك في اختبارات الدمي  جفاف العين أو العين المائية أو الزغللة  احمرار أو عدوى العين  عسر الهضم  تورم في القدمين أو الذراعين  نزيف اللثة  ارتفاع ضغط الدم  الشعور بالدوار  اضطرابات في التذوق  الحكة  ضعف الذاكرة  تساقط الشعر  حساسية جلد اليدين والقدمين )متالزمة ضعف الحس االحمراري بالمار بالنتاري  مشاكل في األظافر آثار جانبية غير شائعة:  هناك حالة أخرى قد يسببها عقار كادسيال وهي حالة تعرف باسم التضخم العقدي في الكبد. وهذه الحالة تسبب تغير بنية الكبد وتغير وظائفه. وبمرور الوقت، فقد يؤدي ذلك إلى أعراا مثل اإلحساس المتضخم أو التورم في البطن بسبب تراكم السوائل أو النزيف من األوعية الدموية في المرىء أو الشرج.  وفي حالة تسرب محلول كادسيال إلى المنطقة حول مكان الحقن فقد يحدث ألم أو احمرار في الجلد أو تورم في مكان المحلول. في حالة حدوث أي من اآلثار الجانبية بعد توقف العالج بكادسيال، تحدث إلى طبيبك أو ممرضتك وأخبرهم بأنك تعالج بعقار كادسيال.</p><p>تسجيل اآلثار الجانبية: في حالة حدوث أي من اآلثار الجانبية، تحدث إلى طبيبك أو ممرضتك. وهذا يشمل أية آثار جانبية غير مذكورة في هذه النشرة. ويمكنك تسجيل اآلثار الجانبية مباشرة بهدف إعطاء المزيد من المعلومات حول سالمة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يتم تخزين عقار كادسيال من قبل أخصائيي الرعاية الصحية في المستشفى أو في العيادة  يحفظ هذا الدواء بعيدا عن متناول األطفال.  ال يستخدم هذا الدواء بعد تاريخ انتهاء الصالحية المدون على العبوة الخارجية. ويشير تاريخ االنتهاء إلى اليوم األخير من الشهر.  يحفظ بالثالجة في درجة حرارة من 2 إلى 8 درجة مئوية وال يجمد.  عند تجهيز المحلول للحقن الوريدي يكون المحلول مناسبا لحقنه خالل 24 ساعة في درجة حرارة من 2 إلى 8 درجة مئوية وبعدها يتم التخلص منه.  يجب عدم التخلص من الدواء في مياه الصرف أو المخلفات المنزلية. اسألي الصيدلي عن كيفية التخلص من األدوية التي لم تعد مستخدمة. وهذه التدابير سوف تساعدك على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحتوي عقار كادسيال على:  المادة الفعالة تراستوزوماب إمتانسين.  كل قارورة مصممة لتحوي 100 ملغ على شكل مسحوق مركز للمحلول ومعدة الستخدام مرة واحدة تعطي 5 مل من 20 ملغ / مل من تراستوزوماب إمتانسين.  كل قارورة مصممة لتحوي 160 ملغ على شكل مسحوق مركز للمحلول ومعدة الستخدام مرة واحدة تعطي 8 مل من 20 ملغ / مل من تراستوزوماب إمتانسين.  العناصر األخرى هي حما السكسينيك، وهيدروكسيد الصوديوم )انظر الجزء الثاني بعنوان &quot;معلومات هامة عن بعا العناصر المكونة لعقار كادسيالي، والسكروز، وبوليسوربيت 20.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>شكل عقار كادسيال ومحتويات العبوة:  كادسيال مسحوق جاف أبيا فاتح أو غامق مركز للمحلول معبأ في قوارير زجاجية.  متوفر كادسيال في عبوات تحتوي على قارورة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إف. هوفمان &ndash; ال روش المحدودة، 124 جرينزاشيرستراس، سي إتش &ndash; 4070 بازل، سويسرا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر تحديث لهذه النشرة بتاريخ مايو 2019
لإلبالغ عن أي آثار جانبية:
 المملكة العربية السعودية:
- المركز الوطني للتيقظ والسالمة الدوائية )NPCي
+966112057662 :فاكس o
234 – 2356 – 2317 :داخلي + 966 - 11 - 2038222 :هاتف o
o مركز االتصال الموحد 19999
npc.drug@sfda.gov.sa :اإللكتروني البريد o
www.sfda.gov.sa/npc :اإللكتروني الموقع o
دول مجلس التعاون الخليجي األخرى:
- يرجى االتصال بالهيئة المختصة ذات الصلة.
هذا الدواء
- هذا الدواء منتج يؤثر على صحتك واستهالكه بطريقة مخالفة للتعليمات يعرا حياتك
للخطر.
- اتبع إرشادات الطبيب وطريقة االستخدام وتعليمات الصيدلي الذي باع لك هذا الدواء.
- الطبيب والصيدلي هم خبراء في األدوية وفوائدها ومخاطرها.
- ال تتوقف من تلقاء نفسك عن العالج الموصوف لك.
- ال تكرر نفس الوصفة الطبية من تلقاء نفسك دور استشارة الطبيب.
- تحفظ جميع األدوية بعيدا عن متناول األطفال.
مجلس وزراء الصحة العرب
اتحاد الصيادلة العرب
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Kadcyla 100 mg powder for concentrate for solution for infusion.
Kadcyla 160 mg powder for concentrate for solution for infusion.
WARNING: HEPATOTOXICITY, CARDIAC TOXICITY, EMBRYO-FETAL TOXICITY
 
Hepatotoxicity:   Serious hepatotoxicity has been reported, including liver failure and death in patients treated with KADCYLA. Monitor serum transaminases and bilirubin prior to initiation of KADCYLA treatment and prior to each KADCYLA dose. Reduce dose or discontinue KADCYLA as appropriate in cases of increased serum transaminases or total bilirubin. (4.2, 4.4)
Cardiac Toxicity:  KADCYLA administration may lead to reductions in left ventricular ejection fraction (LVEF).  Evaluate left ventricular function in all patients prior to and during treatment with KADCYLA.  Withhold treatment for clinically significant decrease in left ventricular function. (4.2, 4.4)
Embryo-Fetal Toxicity:  Exposure to KADCYLA during pregnancy can result in embryo-fetal harm.  Advise patients of these risks and the need for effective contraception. (4.4, 4.6)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                KADCYLA (ado-trastuzumab emtansine) is a HER2-targeted antibody-drug conjugate (ADC) which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 (a maytansine derivative) via the stable thioether linker MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate). Emtansine refers to the MCC-DM1 complex. 
The antibody trastuzumab, is a well characterized recombinant monoclonal antibody product produced by mammalian (Chinese hamster ovary) cells, and the small molecule components (DM1 and MCC) are produced by chemical synthesis. Ado-trastuzumab emtansine contains an average of 3.5 DM1 molecules per antibody.  Ado-trastuzumab emtansine has the following chemical structure: 










Note:  The bracketed structure is DM1 plus MCC which represents the emtansine component.  The n is, on average, 3.5 DM1 molecules per trastuzumab (Mab) molecule.

KADCYLA (ado-trastuzumab emtansine) is a sterile, white to off-white preservative free lyophilized powder in single-dose vials.  Each vial contains 100 mg or 160 mg ado-trastuzumab emtansine.  Following reconstitution, each single-dose vial contains ado-trastuzumab emtansine (20 mg/mL), polysorbate 20 [0.02% (w/v)], sodium succinate (10 mM), and sucrose [6% (w/v)] with a pH of 5.0.  The resulting solution containing 20 mg/mL ado-trastuzumab emtansine is administered by intravenous infusion following dilution. 
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lyophilized powder in single-dose vials: 100 mg per vial or 160 mg per vial of ado-trastuzumab emtansine. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Metastatic Breast Cancer (MBC)</strong></p><p dir="ltr"><strong>KADCYLA&reg;, as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>Received prior therapy for metastatic disease, or</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Developed disease recurrence during or within six months of completing adjuvant therapy.</strong></p></li></ul><p dir="ltr"><strong>Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA [see Posology and method of administration (4.2)].</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Early Breast Cancer (EBC)&nbsp;</strong></p><p dir="ltr"><strong>KADCYLA, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab -based treatment.&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA [see Posology and method of administration (4.2)].</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Patient Selection</strong></p><p dir="ltr"><strong>Select patients based on HER2 protein overexpression or HER2 gene amplification in tumor specimens [see Therapeutic indications (4.1), Pharmacodynamic properties, Clinical efficacy and safety (5.1)].&nbsp; Assessment of HER2 protein overexpression and/or HER2 gene amplification should be performed using FDA-approved tests specific for breast cancers by laboratories with demonstrated proficiency. Information on the FDA-approved tests for the detection of HER2 protein overexpression and HER2 gene amplification is available at: http://www.fda.gov/CompanionDiagnostics.</strong></p><p dir="ltr"><strong>Improper assay performance, including use of sub-optimally fixed tissue, failure to utilize specified reagents, deviation from specific assay instructions, and failure to include appropriate controls for assay validation, can lead to unreliable results.&nbsp;</strong></p><p>&nbsp;</p><p><strong>Recommended Doses and Schedules</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Do not substitute trastuzumab for or with KADCYLA.</strong></p><p dir="ltr"><strong>The recommended dose of KADCYLA is 3.6&nbsp;mg/kg given as an intravenous infusion every&nbsp;3&nbsp;weeks (21-day cycle). Do not administer KADCYLA at doses greater than 3.6 mg/kg.&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>Closely monitor the infusion site for possible subcutaneous infiltration during drug administration [see Special warnings and precautions for use (4.4)].</strong></p><p dir="ltr"><strong>First infusion: Administer infusion over 90 minutes.&nbsp; Observe patients during the infusion and for at least 90 minutes following the initial dose for fever, chills, or other infusion-related reactions [see Special warnings and precautions for use (4.4)].&nbsp;</strong></p><p dir="ltr"><strong>Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated.&nbsp; Observe patients during the infusion and for at least 30 minutes after infusion.</strong></p><p dir="ltr"><strong>Metastatic Breast Cancer (MBC)</strong></p><p dir="ltr"><strong>Patients with MBC should receive treatment until disease progression or unmanageable toxicity.</strong></p><p dir="ltr"><strong>Early Breast Cancer (EBC)</strong></p><p dir="ltr"><strong>Patients with EBC should receive treatment for a total of 14 cycles unless there is disease recurrence or unmanageable toxicity.</strong></p><p>&nbsp;</p><p><strong>Dose Modifications</strong></p><p dir="ltr"><strong>Do not re-escalate the KADCYLA dose after a dose reduction is made.</strong></p><p dir="ltr"><strong>If a planned dose is delayed or missed, administer as soon as possible; do not wait until the next planned cycle.&nbsp; Adjust the schedule of administration to maintain a 3-week interval between doses.&nbsp; Administer the infusion at the dose and rate the patient tolerated in the most recent infusion.</strong></p><p dir="ltr"><strong>Slow or interrupt the infusion rate of KADCYLA if the patient develops an infusion-related reaction.&nbsp; Permanently discontinue KADCYLA for life-threatening infusion-related reactions [see Special warnings and precautions for use (4.4)].&nbsp;</strong></p><p dir="ltr"><strong>Management of increased serum transaminases, hyperbilirubinemia, left ventricular dysfunction, thrombocytopenia, pulmonary toxicity or peripheral neuropathy may require temporary interruption, dose reduction or treatment discontinuation of KADCYLA as per guidelines provided in Tables 1 and 2.</strong></p><p dir="ltr"><strong>Table&nbsp;1 Recommended Dose Reduction Schedule for Adverse Reactions</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Dose Reduction Schedule</strong></p></td><td><p dir="ltr"><strong>Dose Level</strong></p></td></tr><tr><td><p dir="ltr"><strong>Starting dose</strong></p></td><td><p dir="ltr"><strong>3.6 mg/kg</strong></p></td></tr><tr><td><p dir="ltr"><strong>First dose reduction</strong></p></td><td><p dir="ltr"><strong>3 mg/kg</strong></p></td></tr><tr><td><p dir="ltr"><strong>Second dose reduction</strong></p></td><td><p dir="ltr"><strong>2.4 mg/kg</strong></p></td></tr><tr><td><p dir="ltr"><strong>Requirement for further dose reduction</strong></p></td><td><p dir="ltr"><strong>Discontinue treatment</strong></p></td></tr></tbody></table><p dir="ltr"><strong>Table&nbsp;2 Dose Modification Guidelines for KADCYLA</strong></p><table><tbody><tr><td colspan="3"><p dir="ltr"><strong>Dose Modifications for Patients with MBC</strong></p></td></tr><tr><td><p dir="ltr"><strong>Adverse reaction</strong></p></td><td><p dir="ltr"><strong>Severity</strong></p></td><td><p dir="ltr"><strong>Treatment modification</strong></p></td></tr><tr><td rowspan="3"><p dir="ltr"><strong>Increased Transaminase (AST/ALT)</strong></p></td><td><p dir="ltr"><strong>Grade 2<br />(&gt;&nbsp;2.5 to &le; 5&times; the ULN)</strong></p></td><td><p dir="ltr"><strong>Treat at the same dose level.</strong></p></td></tr><tr><td><p dir="ltr"><strong>Grade 3<br />(&gt;&nbsp;5 to &le; 20&times; the ULN)</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA until AST/ALT recovers to Grade &le; 2, and then reduce one dose level</strong></p></td></tr><tr><td><p dir="ltr"><strong>Grade 4<br />(&gt;&nbsp;20&times; the ULN)</strong></p></td><td><p dir="ltr"><strong>Discontinue KADCYLA</strong></p></td></tr><tr><td rowspan="3"><p dir="ltr"><strong>Hyperbilirubinemia</strong></p></td><td><p dir="ltr"><strong>Grade 2<br />(&gt;&nbsp;1.5 to &le; 3&times; the ULN)</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA until total bilirubin recovers to Grade &le; 1, and then treat at the same dose level.</strong></p></td></tr><tr><td><p dir="ltr"><strong>Grade 3<br />(&gt;&nbsp;3 to &le; 10&times; the ULN)</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA until total bilirubin recovers to Grade &le; 1 and then reduce one dose level.</strong></p></td></tr><tr><td><p dir="ltr"><strong>Grade 4<br />(&gt;&nbsp;10&times; the ULN)</strong></p></td><td><p dir="ltr"><strong>Discontinue KADCYLA</strong></p></td></tr><tr><td><p dir="ltr"><strong>Drug Induced Liver Injury (DILI)</strong></p></td><td><p dir="ltr"><strong>Serum transaminases &gt; 3 x ULN and concomitant total bilirubin &gt; 2 &times; ULN</strong></p></td><td><p dir="ltr"><strong>Permanently discontinue KADCYLA in the absence of another likely cause for the elevation of liver enzymes and bilirubin, e.g. liver metastasis or concomitant medication</strong></p></td></tr><tr><td><p dir="ltr"><strong>Nodular Regenerative Hyperplasia (NRH)</strong></p></td><td><p dir="ltr"><strong>All Grades</strong></p></td><td><p dir="ltr"><strong>Permanently discontinue KADCYLA</strong></p></td></tr><tr><td rowspan="2"><p dir="ltr"><strong>Thrombocytopenia</strong></p></td><td><p dir="ltr"><strong>Grade 3&nbsp;</strong></p><p dir="ltr"><strong>(25,000 to &lt;&nbsp;50,000/mm3)</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA until platelet count recovers to Grade&nbsp;&le; 1 (&ge; 75,000/mm3), and then treat at the same dose level</strong></p></td></tr><tr><td><p dir="ltr"><strong>Grade 4</strong></p><p dir="ltr"><strong>(&lt;&nbsp;25,000/mm3)</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA until platelet count recovers to Grade&nbsp;&le; 1 (&ge; 75,000/mm3), and then reduce one dose level</strong></p></td></tr><tr><td rowspan="5"><p dir="ltr"><strong>Left Ventricular Dysfunction&nbsp;</strong></p></td><td><p dir="ltr"><strong>Symptomatic CHF</strong></p></td><td><p dir="ltr"><strong>Discontinue KADCYLA</strong></p></td></tr><tr><td><p dir="ltr"><strong>LVEF &lt; 40%</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA</strong></p><p dir="ltr"><strong>Repeat LVEF assessment within 3 weeks. If LVEF &lt; 40% is confirmed, discontinue KADCYLA</strong></p></td></tr><tr><td><p dir="ltr"><strong>LVEF 40% to &le; 45% and decrease is &ge; 10% points from baseline</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA</strong></p><p dir="ltr"><strong>Repeat LVEF assessment within 3 weeks. If the LVEF has not recovered to within 10% points from baseline, discontinue KADCYLA</strong></p></td></tr><tr><td><p dir="ltr"><strong>LVEF 40% to &le; 45% and decrease is &lt; 10% points from baseline</strong></p></td><td><p dir="ltr"><strong>Continue treatment with KADCYLA.</strong></p><p dir="ltr"><strong>Repeat LVEF assessment within 3 weeks.</strong></p></td></tr><tr><td><p dir="ltr"><strong>LVEF &gt; 45%</strong></p></td><td><p dir="ltr"><strong>Continue treatment with KADCYLA.</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pulmonary Toxicity</strong></p></td><td><p dir="ltr"><strong>Interstitial lung disease (ILD) or pneumonitis</strong></p></td><td><p dir="ltr"><strong>Permanently discontinue KADCYLA</strong></p></td></tr><tr><td><p dir="ltr"><strong>Peripheral Neuropathy</strong></p></td><td><p dir="ltr"><strong>Grade 3-4</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA until resolution Grade &le;&nbsp; 2</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>Dose Modification Guidelines for EBC</strong></p></td></tr><tr><td><p dir="ltr"><strong>Adverse reaction</strong></p></td><td><p dir="ltr"><strong>Severity</strong></p></td><td><p dir="ltr"><strong>Treatment modification</strong></p></td></tr><tr><td rowspan="2"><p dir="ltr"><strong>Increased Alanine Transaminase (ALT)</strong></p></td><td><p dir="ltr"><strong>Grade 2-3<br />(&gt; 3.0 to &le; 20 &times; ULN on day of scheduled treatment)</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA until ALT recovers to Grade &le; 1, and then reduce one dose level</strong></p></td></tr><tr><td><p dir="ltr"><strong>Grade 4<br />(&gt; 20 &times; ULN at any time)</strong></p></td><td><p dir="ltr"><strong>Discontinue KADCYLA</strong></p></td></tr><tr><td rowspan="3"><p dir="ltr"><strong>Increased Aspartate Transaminase (AST)</strong></p></td><td><p dir="ltr"><strong>Grade 2<br />(&gt; 3.0 to &le; 5 &times; ULN on day of scheduled treatment)&nbsp;</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA until AST recovers to Grade &le; 1, and then treat at the same dose level</strong></p></td></tr><tr><td><p dir="ltr"><strong>Grade 3<br />(&gt; 5 to &le; 20 &times; ULN on day of scheduled treatment)&nbsp;</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA until AST recovers to Grade &le; 1, and then reduce one dose level</strong></p></td></tr><tr><td><p dir="ltr"><strong>Grade 4<br />(&gt; 20 &times; ULN at any time)&nbsp;</strong></p></td><td><p dir="ltr"><strong>Discontinue KADCYLA</strong></p></td></tr><tr><td rowspan="2"><p dir="ltr"><strong>Hyperbilirubinemia</strong></p></td><td><p dir="ltr"><strong>TBILI<br />&gt; 1.0 to &le; 2.0 &times; the ULN on day of scheduled treatment&nbsp;</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA until total bilirubin recovers to &le; 1.0 &times; ULN, and then reduce one dose level</strong></p></td></tr><tr><td><p dir="ltr"><strong>TBILI<br />&gt; 2 &times; ULN at any time&nbsp;</strong></p></td><td><p dir="ltr"><strong>Discontinue KADCYLA</strong></p></td></tr><tr><td><p dir="ltr"><strong>Nodular Regenerative Hyperplasia (NRH)</strong></p></td><td><p dir="ltr"><strong>All Grades</strong></p></td><td><p dir="ltr"><strong>Permanently discontinue KADCYLA</strong></p></td></tr><tr><td rowspan="2"><p dir="ltr"><strong>Thrombocytopenia</strong></p></td><td><p dir="ltr"><strong>Grade 2-3 on day of scheduled treatment<br />(25,000 to &lt; 75,000/mm3)</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA until platelet count recovers to Grade &le; 1 (&ge; 75,000/mm3), and then treat at the same dose level. If a patient requires 2 delays due to thrombocytopenia, consider reducing dose by one level.</strong></p></td></tr><tr><td><p dir="ltr"><strong>Grade 4 at any time<br />&lt; 25,000/mm3</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA until platelet count recovers to Grade &le; 1 (&ge; 75,000/mm3), and then reduce one dose level.</strong></p></td></tr><tr><td rowspan="4"><p dir="ltr"><strong>Left Ventricular Dysfunction&nbsp;</strong></p></td><td><p dir="ltr"><strong>LVEF &lt; 45%</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA<br />Repeat LVEF assessment within 3 weeks. If LVEF &lt; 45% is confirmed, discontinue KADCYLA.&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>LVEF 45% to &lt; 50% and decrease is &ge; 10% points from baseline*</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA<br />Repeat LVEF assessment within 3 weeks. If the LVEF remains &lt; 50% and has not recovered to &lt; 10% points from baseline, discontinue KADCYLA.&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>LVEF 45% to &lt; 50% and decrease is &lt; 10% points from baseline*</strong></p></td><td><p dir="ltr"><strong>Continue treatment with KADCYLA.<br />Repeat LVEF assessment within 3 weeks.&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>LVEF &ge; 50%</strong></p></td><td><p dir="ltr"><strong>Continue treatment with KADCYLA.&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Heart Failure</strong></p></td><td><p dir="ltr"><strong>Symptomatic CHF,</strong></p><p dir="ltr"><strong>Grade 3-4 LVSD or Grade 3-4 heart failure, or</strong></p><p dir="ltr"><strong>Grade 2 heart failure<br />accompanied by LVEF &lt; 45%&nbsp;</strong></p></td><td><p dir="ltr"><strong>Discontinue KADCYLA</strong></p></td></tr><tr><td><p dir="ltr"><strong>Peripheral Neuropathy</strong></p></td><td><p dir="ltr"><strong>Grade 3-4</strong></p></td><td><p dir="ltr"><strong>Do not administer KADCYLA until resolution&nbsp; Grade &le; 2</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pulmonary Toxicity</strong></p></td><td><p dir="ltr"><strong>Interstitial lung disease (ILD) or pneumonitis</strong></p></td><td><p dir="ltr"><strong>Permanently discontinue KADCYLA</strong></p></td></tr><tr><td rowspan="2"><p dir="ltr"><strong>Radiotherapy-Related Pneumonitis</strong></p></td><td><p dir="ltr"><strong>Grade 2</strong></p></td><td><p dir="ltr"><strong>Discontinue KADCYLA if not resolving with standard treatment</strong></p></td></tr><tr><td><p dir="ltr"><strong>Grade 3-4</strong></p></td><td><p dir="ltr"><strong>Discontinue KADCYLA</strong></p></td></tr></tbody></table><p dir="ltr"><strong>ALT&nbsp;=&nbsp;alanine transaminase; AST&nbsp;=&nbsp;aspartate transaminase, CHF = congestive heart failure, DILI = Drug Induced Liver Injury; LVEF&nbsp;=&nbsp;left ventricular ejection fraction, LVSD&nbsp;=&nbsp;left ventricular systolic dysfunction, TBILI = Total Bilirubin, ULN&nbsp;=&nbsp;upper limit of normal</strong></p><p dir="ltr"><strong>*Prior to starting KADCYLA treatment</strong></p><p>&nbsp;</p><p><strong>Preparation for Administration</strong></p><p dir="ltr"><strong>In order to prevent medication errors, it is important to check the vial labels to ensure that the drug being prepared and administered is KADCYLA (ado-trastuzumab emtansine) and not trastuzumab.</strong></p><p dir="ltr"><strong>Administration:</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>Administer KADCYLA as an intravenous infusion only with a 0.2 or 0.22 micron in-line polyethersulfone (PES) filter.&nbsp; Do not administer as an intravenous push or bolus.&nbsp;&nbsp;</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Do not mix KADCYLA, or administer as an infusion, with other medicinal products.&nbsp;</strong></p></li></ul><p>&nbsp;</p><p dir="ltr"><strong>Reconstitution:</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>Use aseptic technique for reconstitution and preparation of dosing solution. Appropriate procedures for the preparation of chemotherapeutic drugs should be used.</strong></p></li></ul><ul><li dir="ltr"><p dir="ltr"><strong>Using a sterile syringe, slowly inject 5 mL of Sterile Water for Injection into the 100 mg KADCYLA vial, or 8 mL of Sterile Water for Injection into the 160 mg KADCYLA vial to yield a solution containing 20 mg/mL.&nbsp; Swirl the vial gently until completely dissolved.&nbsp; Do not shake.&nbsp; Inspect the reconstituted solution for particulates and discoloration.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>The&nbsp;reconstituted solution should be clear to slightly opalescent and free of visible particulates.&nbsp; The color of the reconstituted solution should be colorless to pale brown.&nbsp; Do not use if the reconstituted solution contains visible particulates or is cloudy or discolored.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>The reconstituted lyophilized vials should be used immediately following reconstitution with Sterile Water for Injection.&nbsp; If not used immediately, the reconstituted KADCYLA vials can be stored for up to 24 hours in a refrigerator at 2&ordm;C to 8&ordm;C (36&deg;F to 46&deg;F); discard unused KADCYLA after 24 hours.&nbsp; Do not freeze.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>The reconstituted product contains no preservative and is intended for single-dose only.&nbsp;&nbsp;</strong></p></li></ul><p>&nbsp;</p><p dir="ltr"><strong>Dilution:</strong></p><p dir="ltr"><strong>Determine the correct dose (mg) of KADCYLA [see Posology and method of administration (4.2)].</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>Calculate the volume of the 20 mg/mL reconstituted KADCYLA solution needed.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Withdraw this amount from the vial and add it to an infusion bag containing 250 mL of 0.9% Sodium Chloride Injection.&nbsp; Do not use Dextrose (5%) solution.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Gently invert the bag to mix the solution in order to avoid foaming.&nbsp;</strong></p></li><li dir="ltr"><p dir="ltr"><strong>The diluted KADCYLA infusion solution should be used immediately.&nbsp; If not used immediately, the solution may be stored in a refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 24 hours prior to use.&nbsp; This storage time is additional to the time allowed for the reconstituted vials.&nbsp; Do not freeze or shake.&nbsp;</strong></p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                None.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hepatotoxicity<br />Hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases, has been observed in clinical trials with KADCYLA [see Undesirable Effects (4.8)]. &nbsp;Serious hepatotoxicity, including 3 fatal cases, has been observed in clinical trials (n=1624) with KADCYLA as single-agent. All fatal cases occurred in MBC clinical trials with KADCYLA, which included severe drug-induced liver injury and associated hepatic encephalopathy. &nbsp;Some of the patients experiencing hepatotoxicity had comorbidities and/or concomitant medications with known hepatotoxic potential. &nbsp;<br />Monitor serum transaminases and bilirubin prior to initiation of KADCYLA treatment and prior to each KADCYLA dose. &nbsp;Patients with known active liver disease (such as, hepatitis B virus or hepatitis C virus) were excluded from the EMILIA and KATHERINE studies [see Pharmacodynamic properties, Clinical efficacy and safety (5.1)]. &nbsp;Reduce the dose or discontinue KADCYLA as appropriate in cases of increased serum transaminases and/or total bilirubin [see Posology and method of administration (4.2)]. &nbsp;Permanently discontinue KADCYLA treatment in patients with serum transaminases &gt; 3 x ULN and concomitant total bilirubin &gt; 2 x ULN. &nbsp;KADCYLA has not been studied in patients with serum transaminases &gt; 2.5 x ULN or bilirubin &gt; 1.5 x ULN prior to the initiation of treatment.&nbsp;<br />In clinical trials of KADCYLA, cases of nodular regenerative hyperplasia (NRH) of the liver have been identified from liver biopsies (5 cases out of 1624 treated patients, one of which was fatal). &nbsp;Two of these five cases of NRH were observed in EMILIA and two were observed in KATHERINE [see Undesirable Effects (4.8)]. NRH is a rare liver condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules; NRH may lead to non-cirrhotic portal hypertension. The diagnosis of NRH can be confirmed only by histopathology. NRH should be considered in all patients with clinical symptoms of portal hypertension and/or cirrhosis-like pattern seen on the computed tomography (CT) scan of the liver but with normal transaminases and no other manifestations of cirrhosis. &nbsp;Upon diagnosis of NRH, KADCYLA treatment must be permanently discontinued.</p><p>Left Ventricular Dysfunction<br />Patients treated with KADCYLA are at increased risk of developing left ventricular dysfunction. &nbsp;A decrease of LVEF to &lt; 40% has been observed in patients treated with KADCYLA. Serious cases of heart failure, with no fatal cases, have been observed in clinical trials with KADCYLA. In EMILIA, left ventricular dysfunction occurred in 1.8% of patients in the KADCYLA-treated group and 3.3% of patients in the lapatinib plus capecitabine-treated group. In KATHERINE, left ventricular dysfunction occurred in 0.4% of patients in the KADCYLA-treated group and 0.6% of patients in the trastuzumab-treated group [see Undesirable Effects (4.8)].&nbsp;<br />Assess LVEF prior to initiation of KADCYLA and at regular intervals (e.g. every three months) during treatment to ensure the LVEF is within the institution&rsquo;s normal limits. &nbsp;Treatment with KADCYLA has not been studied in patients with LVEF &lt; 50% prior to initiation of treatment.&nbsp;<br />For patients with MBC, if, at routine monitoring, LVEF is &lt; 40%, or is 40% to 45% with a 10% or greater absolute decrease below the pretreatment value, withhold KADCYLA and repeat LVEF assessment within approximately 3 weeks. &nbsp;Permanently discontinue KADCYLA if the LVEF has not improved or has declined further.&nbsp;<br />For patients with EBC, if, at routine monitoring, LVEF is &lt; 45%, or is 45% to 49% with a 10% or greater absolute decrease below the pretreatment value, withhold KADCYLA and repeat LVEF assessment within approximately 3 weeks. &nbsp;Permanently discontinue KADCYLA if the LVEF has not improved or has declined further [see Posology and method of administration (4.2)]. &nbsp;<br />Patients with a history of symptomatic congestive heart failure (CHF), serious cardiac arrhythmia, or history of myocardial infarction or unstable angina within 6 months were excluded from the EMILIA and KATHERINE studies [see Pharmacodynamic properties, Clinical efficacy and safety (5.1)].&nbsp;</p><p>Embryo-Fetal Toxicity&nbsp;<br />KADCYLA can cause fetal harm when administered to a pregnant woman. &nbsp;Cases of oligohydramnios, and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities and neonatal death were observed in the post-marketing setting in patients treated with trastuzumab, the antibody component of KADCYLA. DM1, the cytotoxic component of KADCYLA, can cause embryo-fetal toxicity based on its mechanism of action.&nbsp;<br />Verify the pregnancy status of females of reproductive potential prior to the initiation of KADCYLA. &nbsp;Advise pregnant women and females of reproductive potential that exposure to KADCYLA during pregnancy or within 7 months prior to conception can result in fetal harm. &nbsp;Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of KADCYLA [see Fertility, pregnancy and lactation (4.6)].&nbsp;</p><p>Pulmonary Toxicity<br />Cases of interstitial lung disease (ILD), including pneumonitis, some leading to acute respiratory distress syndrome or fatal outcome have been reported in clinical trials with KADCYLA. &nbsp;Signs and symptoms include dyspnea, cough, fatigue, and pulmonary infiltrates. &nbsp;<br />In patients with MBC, pneumonitis was reported at an incidence of 0.8% (7 out of 884 treated patients), with one case of Grade 3 pneumonitis. The overall incidence of pneumonitis was 1.2% in EMILIA. In KATHERINE, pneumonitis was reported at an incidence of 1.1% (8 out of 740 patients treated with KADCYLA), with one case of Grade 3 pneumonitis.&nbsp;<br />Radiation pneumonitis was reported at an incidence of 1.8% (11 out of 623 patients treated with adjuvant radiotherapy and KADCYLA), with 2 cases of Grade 3 radiation pneumonitis [see Undesirable Effects (4.8)].&nbsp;<br />Permanently discontinue treatment with KADCYLA in patients diagnosed with ILD or pneumonitis. For patients with radiation pneumonitis in the adjuvant setting, KADCYLA should be permanently discontinued for Grade &ge; 3 or for Grade 2 not responding to standard treatment [see Posology and method of administration (4.2)].</p><p>Patients with dyspnea at rest due to complications of advanced malignancy, co-morbidities, and receiving concurrent pulmonary radiation therapy may be at increased risk of pulmonary toxicity.</p><p>Infusion-Related Reactions, Hypersensitivity Reactions<br />Treatment with KADCYLA has not been studied in patients who had trastuzumab permanently discontinued due to infusion-related reactions (IRRs) and/or hypersensitivity; treatment with KADCYLA is not recommended for these patients.<br />Infusion-related reactions, characterized by one or more of the following symptoms &minus; flushing, chills, pyrexia, dyspnea, hypotension, wheezing, bronchospasm, and tachycardia have been reported in clinical trials of KADCYLA. &nbsp;In EMILIA, the overall incidence of IRRs in patients treated with KADCYLA was 1.4%. In KATHERINE, the overall incidence of IRRs in patients treated with KADCYLA was 1.6% [see Undesirable Effects (4.8)]. In most patients, these reactions resolved over the course of several hours to a day after the infusion was terminated. &nbsp;KADCYLA treatment should be interrupted in patients with severe IRR. &nbsp;KADCYLA treatment should be permanently discontinued in the event of a life-threatening IRR [see Posology and method of administration (4.2)]. &nbsp;Patients should be observed closely for IRR reactions, especially during the first infusion. &nbsp;<br />One case of a serious, allergic/anaphylactic-like reaction has been observed in clinical trials of single-agent KADCYLA. &nbsp;Medications to treat such reactions, as well as emergency equipment, should be available for immediate use.</p><p>Hemorrhage<br />Cases of hemorrhagic events, including central nervous system, respiratory, and gastrointestinal hemorrhage, have been reported in clinical trials with KADCYLA. Some of these bleeding events resulted in fatal outcomes. In EMILIA, the overall incidence of hemorrhage was 32% in the KADCYLA-treated group and 16% in the lapatinib plus capecitabine-treated group. The incidence of Grade &ge; 3 hemorrhage was 1.8% in the KADCYLA-treated group and 0.8% in the lapatinib plus capecitabine-treated group. In KATHERINE, the overall incidence of hemorrhage was 29% in the KADCYLA-treated group and 10% in the trastuzumab-treated group. The incidence of Grade &ge; 3 hemorrhage was 0.4% in the KADCYLA-treated group, with one fatal case of intracranial hemorrhage, and 0.3% in the trastuzumab-treated group [see Undesirable Effects (4.8)]. &nbsp;Although, in some of the observed cases the patients were also receiving anti-coagulation therapy, antiplatelet therapy, or had thrombocytopenia, in others there were no known additional risk factors. &nbsp;Use caution with these agents and consider additional monitoring when concomitant use is medically necessary.</p><p>Thrombocytopenia<br />Thrombocytopenia, or decreased platelet count, was reported in clinical trials of KADCYLA (145 of 1624 treated patients with Grade &ge; 3; 494 of 1624 treated patients with any Grade). &nbsp;The majority of these patients had Grade 1 or 2 events (&lt; LLN to &ge; 50,000/mm3) with the nadir occurring by day 8 and generally improving to Grade 0 or 1 (&ge; 75,000/mm3) by the next scheduled dose. &nbsp;In clinical trials of KADCYLA, the incidence and severity of thrombocytopenia were higher in Asian patients. &nbsp; &nbsp;<br />In EMILIA, the overall incidence of thrombocytopenia was 31% in the KADCYLA-treated group and 3.3% in the lapatinib plus capecitabine-treated group [see Undesirable Effects (4.8)]. &nbsp;The incidence of Grade &ge; 3 thrombocytopenia was 15% in the KADCYLA-treated group and 0.4% in the lapatinib plus capecitabine-treated group. &nbsp;In Asian patients, the incidence of Grade &ge; 3 thrombocytopenia was 45% in the KADCYLA-treated group and 1.3% in the lapatinib plus capecitabine-treated group.<br />In KATHERINE, the overall incidence of thrombocytopenia was 29% in the KADCYLA-treated group and 2.4% in the trastuzumab-treated group [see Undesirable Effects (4.8)]. &nbsp;The incidence of Grade &ge; 3 thrombocytopenia was 6% in the KADCYLA-treated group and 0.3% in the trastuzumab-treated group. &nbsp;In Asian patients, the incidence of Grade &ge; 3 thrombocytopenia was 19% in the KADCYLA-treated group and 0% in the trastuzumab-treated group. The overall incidence of thrombocytopenia in the KADCYLA-treated group for Asian patients was 50%.<br />Monitor platelet counts prior to initiation of KADCYLA and prior to each KADCYLA dose [see Posology and method of administration (4.2)]. &nbsp;KADCYLA has not been studied in patients with platelet counts &lt; 100,000/mm3 prior to initiation of treatment. &nbsp;In the event of decreased platelet count to Grade &ge; 3 (&lt; 50,000/mm3) do not administer KADCYLA until platelet counts recover to Grade 1 (&ge; 75,000/mm3) [see Posology and method of administration (4.2)]. Closely monitor patients with thrombocytopenia (&lt; 100,000/mm3) and patients on anti-coagulant treatment during treatment with KADCYLA. &nbsp;</p><p>Neurotoxicity<br />Peripheral neuropathy, mainly as Grade 1 and predominantly sensory, was reported in clinical trials of KADCYLA (26 of 1624 treated patients with Grade &ge; 3; 435 of 1624 treated patients with any Grade). &nbsp;In EMILIA, the overall incidence of peripheral neuropathy was 21% in the KADCYLA-treated group and 14% in the lapatinib plus capecitabine-treated group [see Undesirable Effects (4.8)]. &nbsp;The incidence of Grade &ge; 3 peripheral neuropathy was 2.2% in the KADCYLA-treated group and 0.2% in the lapatinib plus capecitabine-treated group. In KATHERINE, the overall incidence of peripheral neuropathy was 32% in the KADCYLA-treated group and 17% in the trastuzumab-treated group. Peripheral neuropathy, including sensory and motor peripheral neuropathy, for KADCYLA treated patients 30% of cases were not resolved at the time of the primary IDFS analysis for KATHERINE. The incidence of Grade &ge; 3 peripheral neuropathy was 1.6% in the KADCYLA-treated group and 0.1% in the trastuzumab-treated group.<br />KADCYLA should be temporarily discontinued in patients experiencing Grade 3 or 4 peripheral neuropathy until resolution to Grade &le; 2. &nbsp;Patients should be clinically monitored on an ongoing basis for signs or symptoms of neurotoxicity [see Preclinical safety data (5.3)]. &nbsp;</p><p>Extravasation&nbsp;<br />In KADCYLA clinical studies, reactions secondary to extravasation have been observed. &nbsp;These reactions, observed more frequently within 24 hours of infusion, were usually mild and comprised erythema, tenderness, skin irritation, pain, or swelling at the infusion site. &nbsp;Specific treatment for KADCYLA extravasation is unknown. The infusion site should be closely monitored for possible subcutaneous infiltration during drug administration.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Drug Interactions</strong></p><p><strong>No formal drug-drug interaction studies with KADCYLA have been conducted.&nbsp; In vitro studies indicate that DM1, the cytotoxic component of KADCYLA, is metabolized mainly by CYP3A4 and to a lesser extent by CYP3A5.&nbsp; Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole) with KADCYLA should be avoided due to the potential for an increase in DM1 exposure and toxicity.&nbsp; Consider an alternate medication with no or minimal potential to inhibit CYP3A4.&nbsp; If concomitant use of strong CYP3A4 inhibitors is unavoidable, consider delaying KADCYLA treatment until the strong CYP3A4 inhibitors have cleared from the circulation (approximately 3 elimination half-lives of the inhibitors) when possible.&nbsp; If a strong CYP3A4 inhibitor is coadministered and KADCYLA treatment cannot be delayed, patients should be closely monitored for adverse reactions. </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Risk Summary</strong></p><p dir="ltr"><strong>KADCYLA can cause fetal harm when administered to a pregnant woman.&nbsp; There are no available data on the use of KADCYLA in pregnant women.&nbsp; Cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death were observed in the postmarketing setting in patients treated with trastuzumab, the antibody component of KADCYLA [see Data].&nbsp; Based on its mechanism of action, the DM1 component of KADCYLA can also cause embryo-fetal harm when administered to a pregnant woman [see Data].&nbsp; Apprise the patient of the potential risks to a fetus.&nbsp; There are clinical considerations if KADCYLA is used in a pregnant woman, or if a patient becomes pregnant within 7 months following the last dose of KADCYLA [see Clinical Considerations].</strong></p><p dir="ltr"><strong>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Clinical Considerations</strong></p><p dir="ltr"><strong>Fetal/Neonatal Adverse Reactions</strong></p><p dir="ltr"><strong>Monitor women who received KADCYLA during pregnancy or within 7 months prior to conception for oligohydramnios. If oligohydramnios occurs, perform fetal testing that is appropriate for gestational age and consistent with community standards of care.&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Data</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Human Data</strong></p><p dir="ltr"><strong>There are no available data on the use of KADCYLA in pregnant women.&nbsp; In the post-marketing setting, cases of oligohydramnios, and of oligohydramnios sequence, manifesting in the fetus as pulmonary hypoplasia, skeletal abnormalities and neonatal death were observed after treatment with trastuzumab during pregnancy. These case reports described oligohydramnios in pregnant women who received trastuzumab either alone or in combination with chemotherapy.&nbsp; In some case reports, amniotic fluid index increased after trastuzumab was stopped.&nbsp; In one case, trastuzumab therapy resumed after amniotic index improved, and oligohydramnios recurred.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Animal Data</strong></p><p dir="ltr"><strong>There were no reproductive and developmental toxicology studies conducted with ado-trastuzumab emtansine.&nbsp; DM1, the cytotoxic component of KADCYLA, disrupts microtubule function.&nbsp; DM1 is toxic to rapidly dividing cells in animals and is genotoxic, suggesting it has the potential to cause embryotoxicity and teratogenicity.&nbsp; In studies where trastuzumab was administered to pregnant cynomolgus monkeys during the period of organogenesis at doses up to 25 mg/kg given twice weekly (about 7 times the clinical dose), trastuzumab crossed the placental barrier during the early (Gestation Days 20 to 50) and late (Gestation Days 120 to 150) phases of gestation.&nbsp; The resulting concentrations of trastuzumab in fetal serum and amniotic fluid were approximately 33% and 25%, respectively, of those present in the maternal serum but were not associated with adverse developmental effects.</strong></p><p>&nbsp;</p><p><strong>Lactation</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Risk Summary&nbsp;</strong></p><p dir="ltr"><strong>There is no information regarding the presence of ado-trastuzumab emtansine in human milk, the effects on the breastfed infant, or the effects on milk production.&nbsp; DM1, the cytotoxic component of KADCYLA, may cause serious adverse reactions in breastfed infants based on its mechanism of action [see Data].&nbsp; Advise women not to breastfeed during treatment and for 7 months following the last dose of KADCYLA.&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Data</strong></p><p dir="ltr"><strong>There were no animal lactation studies conducted with ado-trastuzumab emtansine or the cytotoxic component of KADCYLA (DM1). In lactating cynomolgus monkeys, trastuzumab was present in breast milk at about 0.3% of maternal serum concentrations after pre- (beginning Gestation Day 120) and post-partum (through Post-partum Day 28) doses of 25 mg/kg administered twice weekly (about 7 times the clinical dose of KADCYLA). Infant monkeys with detectable serum levels of trastuzumab did not exhibit any adverse effects on growth or development from birth to 1 month of age.&nbsp;</strong></p><p>&nbsp;</p><p><strong>Females and Males of Reproductive Potential</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy Testing</strong></p><p dir="ltr"><strong>Verify the pregnancy status of females of reproductive potential prior to the initiation of KADCYLA.&nbsp;&nbsp;</strong></p><p><br /><br /><br />&nbsp;</p><p dir="ltr"><strong>Contraception</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Females</strong></p><p dir="ltr"><strong>KADCYLA can cause embryo-fetal harm when administered during pregnancy.&nbsp; Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of KADCYLA [see Fertility, pregnancy and lactation (4.6)].&nbsp;</strong></p><p dir="ltr"><strong>Males</strong></p><p dir="ltr"><strong>Because of the potential for genotoxicity, advise male patients with female partners of reproductive potential to use effective contraception during treatment with KADCYLA and for 4 months following the last dose.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infertility&nbsp;</strong></p><p dir="ltr"><strong>Based on results from animal toxicity studies, KADCYLA may impair fertility in females and males of reproductive potential.&nbsp; It is not known if the effects are reversible [see Preclinical safety data (5.3)].</strong></p><p>&nbsp;</p><p><strong>Pediatric Use</strong></p><p dir="ltr"><strong>Safety and effectiveness of KADCYLA have not been established in pediatric patients.</strong></p><p>&nbsp;</p><p><strong>Geriatric Use</strong></p><p dir="ltr"><strong>Of the 495 patients who were randomized to KADCYLA in EMILIA [see Pharmacodynamic properties, Clinical efficacy and safety (5.1)], 65 patients (13%) were &ge; 65 years of age and 11 patients (2%) were &ge; 75 years of age.&nbsp; In patients &ge; 65 years old (n=138 across both treatment arms) the hazard ratios for progression-free survival (PFS) and overall survival (OS) were 1.06 (95% CI: 0.68, 1.66) and 1.05 (95% CI: 0.58, 1.91), respectively.&nbsp; No overall differences in the safety of KADCYLA were observed in patients aged &ge; 65 compared to patients &lt; 65 years of age. EMILIA did not include sufficient numbers of patients aged &ge; 75 years to draw conclusions on the safety or effectiveness of KADCYLA in this age group.&nbsp;</strong></p><p dir="ltr"><strong>Of the 743 patients who were randomized to KADCYLA in KATHERINE [see Pharmacodynamic properties, Clinical efficacy and safety (5.1)], 58 patients (8%) were &ge; 65 years of age and 2 patients (0.3%) were &ge; 75 years of age.&nbsp; No overall differences in the safety or effectiveness of KADCYLA were observed in patients aged &ge; 65 compared to patients &lt; 65 years of age. KATHERINE did not include sufficient numbers of patients aged &ge; 75 years to draw conclusions on the safety or effectiveness of KADCYLA in this age group.</strong></p><p dir="ltr"><strong>Population pharmacokinetic analysis indicates that age does not have a clinically meaningful effect on the pharmacokinetics of ado-trastuzumab emtansine [see Pharmacokinetic properties (5.2)].</strong></p><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><p dir="ltr"><strong>No dedicated renal impairment trial for KADCYLA has been conducted.&nbsp; Based on the population pharmacokinetics, as well as analysis of Grade 3 or greater adverse reactions and dose modifications, dose adjustments of KADCYLA are not needed in patients with mild (creatinine clearance [CLcr] 60 to 89 mL/min) or moderate (CLcr 30 to 59 mL/min) renal impairment.&nbsp; No dose adjustment can be recommended for patients with severe renal impairment (CLcr less than 30 mL/min) because of the limited data available [see Pharmacokinetic properties (5.2)].</strong></p><p><strong>Hepatic Impairment</strong></p><p dir="ltr"><strong>No adjustment to the starting dose is required for patients with mild or moderate hepatic impairment [see Pharmacokinetic properties (5.2)].&nbsp; KADCYLA was not studied in patients with severe hepatic impairment.&nbsp; Closely monitor patients with hepatic impairment due to known hepatotoxicity observed with KADCYLA [see Warnings and Precautions, Hepatotoxicity (5.1)].</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Trastuzumab emtansine has no or negligible influence on the ability to drive and use machines.&nbsp;</strong></p><p dir="ltr"><strong>The significance of reported adverse reactions such as fatigue, headache, dizziness and blurred vision on the ability to drive or use machines is unknown. Patients experiencing infusion-related reactions should be advised not to drive and use machines until symptoms abate.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>The following adverse reactions are discussed in greater detail in other sections of the label:&nbsp;</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>Hepatotoxicity [See Warnings and Precautions (5.1)]</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Left Ventricular Dysfunction [See Warnings and Precautions (5.1)]</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Embryo-Fetal Toxicity [See Warnings and Precautions (5.1)]</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Pulmonary Toxicity [See Warnings and Precautions (5.1)]</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Infusion-Related Reactions, Hypersensitivity Reactions [See Warnings and Precautions (5.1)]</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Hemorrhage [See Warnings and Precautions (5.1)]</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Thrombocytopenia [See Warnings and Precautions (5.1)]</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Neurotoxicity [See Warnings and Precautions (5.1)]</strong></p></li></ul><p>&nbsp;</p><p dir="ltr"><strong>Clinical Trials Experience&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</strong></p><p dir="ltr"><strong>The data in the WARNINGS AND PRECAUTIONS reflect exposure to KADCYLA as a single agent at 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) in 1624 patients including 884 patients with HER2-positive metastatic breast cancer and 740 patients with HER2-positive early breast cancer (KATHERINE trial).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Metastatic Breast Cancer</strong></p><p dir="ltr"><strong>In clinical trials, KADCYLA has been evaluated as single-agent in 884 patients with HER2-positive metastatic breast cancer.&nbsp; The most common (&ge; 25%) adverse reactions were fatigue, nausea, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, increased transaminases, constipation and epistaxis.</strong></p><p dir="ltr"><strong>The adverse reactions described in Table 3 were identified in patients with HER2-positive metastatic breast cancer treated in the EMILIA trial [see Pharmacodynamic properties, Clinical efficacy and safety (5.1)].&nbsp; Patients were randomized to receive KADCYLA or lapatinib plus capecitabine.&nbsp; The median duration of study treatment was 7.6 months for patients in the KADCYLA-treated group and 5.5 months and 5.3 months for patients treated with lapatinib and capecitabine, respectively.&nbsp;</strong></p><p dir="ltr"><strong>In the EMILIA trial, 43% of patients experienced Grade &ge; 3 adverse reactions in the KADCYLA-treated group compared with 59% of patients in the lapatinib plus capecitabine-treated group.&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>Dose adjustments for KADCYLA were permitted [see Posology and method of administration (4.2)].&nbsp; Thirty-two patients (7%) discontinued KADCYLA due to an adverse reaction, compared with 41 patients (8%) who discontinued lapatinib, and 51 patients (10%) who discontinued capecitabine due to an adverse reaction.&nbsp; The most common adverse reactions leading to KADCYLA discontinuation were thrombocytopenia and increased transaminases.&nbsp; Eighty patients (16%) treated with KADCYLA had adverse reactions leading to dose reductions.&nbsp; The most frequent adverse reactions leading to dose reduction of KADCYLA (in&nbsp;&ge;&nbsp;1% of patients) included thrombocytopenia, increased transaminases, and peripheral neuropathy.&nbsp; Adverse reactions that led to dose delays occurred in 116 (24%) of KADCYLA treated patients.&nbsp; The most frequent adverse reactions leading to a dose delay of KADCYLA (in &ge; 1% of patients) were neutropenia, thrombocytopenia, leukopenia, fatigue, increased transaminases and pyrexia.</strong></p><p dir="ltr"><strong>Table 3 reports the adverse reactions that occurred in patients in the KADCYLA-treated group (n=490) of the EMILIA trial.&nbsp; Selected laboratory abnormalities are shown in Table 4.&nbsp; The most common adverse reactions seen with KADCYLA in the randomized trial (frequency &gt; 25%) were nausea, fatigue, musculoskeletal pain, hemorrhage, thrombocytopenia, increased transaminases, headache, and constipation.&nbsp; The most common NCI&ndash;CTCAE (version 3) Grade &ge; 3 adverse reactions (frequency &gt; 2%) were thrombocytopenia, increased transaminases, anemia, hypokalemia, peripheral neuropathy and fatigue.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 3 Adverse Reactions Occurring in &ge; 10% of Patients on the KADCYLA Treatment Arm in the EMILIA Trial1</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Adverse Reactions&nbsp;</strong></p></td><td colspan="2"><p dir="ltr"><strong>KADCYLA</strong></p><p dir="ltr"><strong>(3.6 mg/kg)</strong></p><p dir="ltr"><strong>n=490</strong></p></td><td colspan="2"><p dir="ltr"><strong>Lapatinib (1250 mg) + Capecitabine (2000 mg/m2)</strong></p><p dir="ltr"><strong>n=488</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>All Grades (%)</strong></p></td><td><p dir="ltr"><strong>Grade 3 &ndash; 4 (%)</strong></p></td><td><p dir="ltr"><strong>All Grades (%)</strong></p></td><td><p dir="ltr"><strong>Grade 3 &ndash; 4 (%)</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Blood and Lymphatic System&nbsp;</strong></p><p dir="ltr"><strong>Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Thrombocytopenia</strong></p></td><td><p dir="ltr"><strong>31</strong></p></td><td><p dir="ltr"><strong>15</strong></p></td><td><p dir="ltr"><strong>3.3</strong></p></td><td><p dir="ltr"><strong>0.4</strong></p></td></tr><tr><td><p dir="ltr"><strong>Anemia</strong></p></td><td><p dir="ltr"><strong>14</strong></p></td><td><p dir="ltr"><strong>4.1</strong></p></td><td><p dir="ltr"><strong>11</strong></p></td><td><p dir="ltr"><strong>2.5</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Gastrointestinal Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Nausea</strong></p></td><td><p dir="ltr"><strong>40</strong></p></td><td><p dir="ltr"><strong>0.8</strong></p></td><td><p dir="ltr"><strong>45</strong></p></td><td><p dir="ltr"><strong>2.5</strong></p></td></tr><tr><td><p dir="ltr"><strong>Constipation</strong></p></td><td><p dir="ltr"><strong>27</strong></p></td><td><p dir="ltr"><strong>0.4</strong></p></td><td><p dir="ltr"><strong>11</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Diarrhea</strong></p></td><td><p dir="ltr"><strong>24</strong></p></td><td><p dir="ltr"><strong>1.6</strong></p></td><td><p dir="ltr"><strong>80</strong></p></td><td><p dir="ltr"><strong>21</strong></p></td></tr><tr><td><p dir="ltr"><strong>Vomiting</strong></p></td><td><p dir="ltr"><strong>19</strong></p></td><td><p dir="ltr"><strong>0.8</strong></p></td><td><p dir="ltr"><strong>30</strong></p></td><td><p dir="ltr"><strong>4.5</strong></p></td></tr><tr><td><p dir="ltr"><strong>Abdominal pain</strong></p></td><td><p dir="ltr"><strong>19</strong></p></td><td><p dir="ltr"><strong>0.8</strong></p></td><td><p dir="ltr"><strong>18</strong></p></td><td><p dir="ltr"><strong>1.6</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dry Mouth</strong></p></td><td><p dir="ltr"><strong>17</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>4.9</strong></p></td><td><p dir="ltr"><strong>0.2</strong></p></td></tr><tr><td><p dir="ltr"><strong>Stomatitis</strong></p></td><td><p dir="ltr"><strong>14</strong></p></td><td><p dir="ltr"><strong>0.2</strong></p></td><td><p dir="ltr"><strong>33</strong></p></td><td><p dir="ltr"><strong>2.5</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>General Disorders and&nbsp;</strong></p><p dir="ltr"><strong>Administration</strong></p></td></tr><tr><td><p dir="ltr"><strong>Fatigue</strong></p></td><td><p dir="ltr"><strong>36</strong></p></td><td><p dir="ltr"><strong>2.5</strong></p></td><td><p dir="ltr"><strong>28</strong></p></td><td><p dir="ltr"><strong>3.5</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pyrexia</strong></p></td><td><p dir="ltr"><strong>19</strong></p></td><td><p dir="ltr"><strong>0.2</strong></p></td><td><p dir="ltr"><strong>8</strong></p></td><td><p dir="ltr"><strong>0.4</strong></p></td></tr><tr><td><p dir="ltr"><strong>Asthenia</strong></p></td><td><p dir="ltr"><strong>18</strong></p></td><td><p dir="ltr"><strong>0.4</strong></p></td><td><p dir="ltr"><strong>18</strong></p></td><td><p dir="ltr"><strong>1.6</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Investigations</strong></p></td></tr><tr><td><p dir="ltr"><strong>Transaminases increased</strong></p></td><td><p dir="ltr"><strong>29</strong></p></td><td><p dir="ltr"><strong>8.0</strong></p></td><td><p dir="ltr"><strong>14</strong></p></td><td><p dir="ltr"><strong>2.5</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Metabolism and Nutrition&nbsp;</strong></p><p dir="ltr"><strong>Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hypokalemia</strong></p></td><td><p dir="ltr"><strong>10</strong></p></td><td><p dir="ltr"><strong>2.7</strong></p></td><td><p dir="ltr"><strong>9</strong></p></td><td><p dir="ltr"><strong>4.7</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Musculoskeletal and Connective&nbsp;</strong></p><p dir="ltr"><strong>Tissue Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Musculoskeletal pain</strong></p></td><td><p dir="ltr"><strong>36</strong></p></td><td><p dir="ltr"><strong>1.8</strong></p></td><td><p dir="ltr"><strong>31</strong></p></td><td><p dir="ltr"><strong>1.4</strong></p></td></tr><tr><td><p dir="ltr"><strong>Arthralgia</strong></p></td><td><p dir="ltr"><strong>19</strong></p></td><td><p dir="ltr"><strong>0.6</strong></p></td><td><p dir="ltr"><strong>8</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Myalgia</strong></p></td><td><p dir="ltr"><strong>14</strong></p></td><td><p dir="ltr"><strong>0.6</strong></p></td><td><p dir="ltr"><strong>3.7</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Nervous System Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Headache</strong></p></td><td><p dir="ltr"><strong>28</strong></p></td><td><p dir="ltr"><strong>0.8</strong></p></td><td><p dir="ltr"><strong>15</strong></p></td><td><p dir="ltr"><strong>0.8</strong></p></td></tr><tr><td><p dir="ltr"><strong>Peripheral neuropathy&nbsp;</strong></p></td><td><p dir="ltr"><strong>21</strong></p></td><td><p dir="ltr"><strong>2.2</strong></p></td><td><p dir="ltr"><strong>14</strong></p></td><td><p dir="ltr"><strong>0.2</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dizziness</strong></p></td><td><p dir="ltr"><strong>10</strong></p></td><td><p dir="ltr"><strong>0.4</strong></p></td><td><p dir="ltr"><strong>11</strong></p></td><td><p dir="ltr"><strong>0.2</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Psychiatric Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Insomnia</strong></p></td><td><p dir="ltr"><strong>12</strong></p></td><td><p dir="ltr"><strong>0.4</strong></p></td><td><p dir="ltr"><strong>9</strong></p></td><td><p dir="ltr"><strong>0.2</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Respiratory, Thoracic, and&nbsp;</strong></p><p dir="ltr"><strong>Mediastinal Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Epistaxis</strong></p></td><td><p dir="ltr"><strong>23</strong></p></td><td><p dir="ltr"><strong>0.2</strong></p></td><td><p dir="ltr"><strong>8</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cough</strong></p></td><td><p dir="ltr"><strong>18</strong></p></td><td><p dir="ltr"><strong>0.2</strong></p></td><td><p dir="ltr"><strong>13</strong></p></td><td><p dir="ltr"><strong>0.2</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dyspnea</strong></p></td><td><p dir="ltr"><strong>12</strong></p></td><td><p dir="ltr"><strong>0.8</strong></p></td><td><p dir="ltr"><strong>8</strong></p></td><td><p dir="ltr"><strong>0.4</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Skin and Subcutaneous Tissue&nbsp;</strong></p><p dir="ltr"><strong>Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Rash</strong></p></td><td><p dir="ltr"><strong>12</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>28</strong></p></td><td><p dir="ltr"><strong>1.8</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Vascular Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hemorrhage</strong></p></td><td><p dir="ltr"><strong>32</strong></p></td><td><p dir="ltr"><strong>1.8</strong></p></td><td><p dir="ltr"><strong>16</strong></p></td><td><p dir="ltr"><strong>0.8</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>1 Grouped terms were used for the following Adverse Reactions:&nbsp;</strong></p><p dir="ltr"><strong>Thrombocytopenia: thrombocytopenia, platelet count decreased</strong></p><p dir="ltr"><strong>Anemia: anemia, hemoglobin decreased&nbsp;</strong></p><p dir="ltr"><strong>Abdominal pain: abdominal pain, abdominal pain upper</strong></p><p dir="ltr"><strong>Stomatitis: stomatitis, mucosal inflammation, oropharyngeal pain&nbsp;</strong></p><p dir="ltr"><strong>Transaminases Increased: transaminases increased, aspartate aminotransferase increased, alanine aminotransferase increased, gamma-glutamyltransferase increased, liver function test abnormal, hepatic enzyme increased, hepatic function abnormal&nbsp;</strong></p><p dir="ltr"><strong>Hypokalemia: hypokalemia, blood potassium decreased</strong></p><p dir="ltr"><strong>Musculoskeletal Pain: muscle spasms, musculoskeletal discomfort, musculoskeletal chest pain, back pain, pain in extremity, bone pain, musculoskeletal pain</strong></p><p dir="ltr"><strong>Peripheral neuropathy: neuropathy peripheral, peripheral sensory neuropathy, peripheral motor neuropathy, paresthesia</strong></p><p dir="ltr"><strong>Hemorrhage: Hemorrhage terms (excl laboratory terms) (SMQ, wide), Hemorrhage laboratory terms (SMQ, narrow).</strong></p><p dir="ltr"><strong>SMQ=standardized MedDRA queries</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The following clinically relevant adverse reactions were reported in &lt; 10% of patients in the KADCYLA-treated group in EMILIA: dyspepsia (9%), urinary tract infection (9%), chills (8%), dysgeusia (8%), neutropenia (7%), peripheral edema (7%), pruritus (6%), hypertension (5%), blood alkaline phosphatase increased (4.7%), vision blurred (4.5%), conjunctivitis (3.9%), dry eye (3.9%), lacrimation increased (3.3%), drug hypersensitivity (2.2%), left ventricular dysfunction (1.8%),&nbsp; infusion-related reaction (1.4%), pneumonitis (1.2%), nodular regenerative hyperplasia (0.4%), portal hypertension (0.4%).</strong></p><p><br />&nbsp;</p><p dir="ltr"><strong>Table 4 Selected Laboratory Abnormalities (EMILIA)</strong></p><table><tbody><tr><td rowspan="2"><p dir="ltr"><strong>Parameter</strong></p></td><td colspan="3"><p dir="ltr"><strong>KADCYLA</strong></p><p dir="ltr"><strong>(3.6 mg/kg)</strong></p></td><td colspan="3"><p dir="ltr"><strong>Lapatinib (1250 mg) + Capecitabine (2000 mg/m2)</strong></p></td></tr><tr><td><p dir="ltr"><strong>All Grades (%)</strong></p></td><td><p dir="ltr"><strong>Grade 3 (%)</strong></p></td><td><p dir="ltr"><strong>Grade 4 (%)</strong></p></td><td><p dir="ltr"><strong>All Grades (%)</strong></p></td><td><p dir="ltr"><strong>Grade 3 (%)</strong></p></td><td><p dir="ltr"><strong>Grade 4 (%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Chemistry</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Increased AST</strong></p></td><td><p dir="ltr"><strong>98</strong></p></td><td><p dir="ltr"><strong>7</strong></p></td><td><p dir="ltr"><strong>0.5</strong></p></td><td><p dir="ltr"><strong>65</strong></p></td><td><p dir="ltr"><strong>3</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Increased ALT</strong></p></td><td><p dir="ltr"><strong>82</strong></p></td><td><p dir="ltr"><strong>5</strong></p></td><td><p dir="ltr"><strong>0.2</strong></p></td><td><p dir="ltr"><strong>54</strong></p></td><td><p dir="ltr"><strong>3</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Decreased potassium</strong></p></td><td><p dir="ltr"><strong>33</strong></p></td><td><p dir="ltr"><strong>3</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>31</strong></p></td><td><p dir="ltr"><strong>6</strong></p></td><td><p dir="ltr"><strong>0.8</strong></p></td></tr><tr><td><p dir="ltr"><strong>Increased bilirubin</strong></p></td><td><p dir="ltr"><strong>17</strong></p></td><td><p dir="ltr"><strong>0.6</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>57</strong></p></td><td><p dir="ltr"><strong>2</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hematology</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Decreased platelet count</strong></p></td><td><p dir="ltr"><strong>83</strong></p></td><td><p dir="ltr"><strong>14</strong></p></td><td><p dir="ltr"><strong>3</strong></p></td><td><p dir="ltr"><strong>21</strong></p></td><td><p dir="ltr"><strong>0.4</strong></p></td><td><p dir="ltr"><strong>0.6</strong></p></td></tr><tr><td><p dir="ltr"><strong>Decreased hemoglobin</strong></p></td><td><p dir="ltr"><strong>60</strong></p></td><td><p dir="ltr"><strong>4</strong></p></td><td><p dir="ltr"><strong>1</strong></p></td><td><p dir="ltr"><strong>64</strong></p></td><td><p dir="ltr"><strong>3</strong></p></td><td><p dir="ltr"><strong>0.2</strong></p></td></tr><tr><td><p dir="ltr"><strong>Decreased neutrophils</strong></p></td><td><p dir="ltr"><strong>39</strong></p></td><td><p dir="ltr"><strong>3</strong></p></td><td><p dir="ltr"><strong>0.6</strong></p></td><td><p dir="ltr"><strong>38</strong></p></td><td><p dir="ltr"><strong>6</strong></p></td><td><p dir="ltr"><strong>2</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>Early Breast Cancer</strong></p><p dir="ltr"><strong>KADCYLA has been evaluated as a single-agent in 740 patients with HER2-positive early breast cancer.&nbsp;</strong></p><p dir="ltr"><strong>The adverse reactions described in Table 5 were identified in patients with HER2-positive early breast cancer treated in the KATHERINE trial [Pharmacodynamic properties, Clinical efficacy and safety (5.1)].&nbsp; Patients were randomized to receive KADCYLA or trastuzumab.&nbsp; The median duration of study treatment was 10 months for patients in the KADCYLA-treated group and 10 months for patients treated with trastuzumab.&nbsp;</strong></p><p dir="ltr"><strong>One hundred and ninety (26%) patients experienced Grade &ge; 3 adverse reactions in the KADCYLA-treated group compared with 111 (15%) patients in the trastuzumab group.&nbsp; One hundred and thirty-three patients (18%) discontinued KADCYLA due to an adverse reaction, compared with 15 patients (2.1%) who discontinued trastuzumab due to an adverse reaction.&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>The most common adverse reactions leading to KADCYLA discontinuation (in &ge; 1% of patients) were platelet count decreased, blood bilirubin increased, ejection fraction decreased, AST increased, ALT increased, and peripheral neuropathy.&nbsp;</strong></p><p dir="ltr"><strong>Dose adjustments for KADCYLA were permitted [see Posology and method of administration (4.2)]. One hundred and six patients (14%) treated with KADCYLA had dose reductions. The most frequent adverse reactions leading to dose reduction of KADCYLA (in&nbsp;&ge;&nbsp;1% of patients) included thrombocytopenia, increased transaminases, blood bilirubin and fatigue.&nbsp; Adverse reactions that led to dose delays occurred in 106 (14%) of KADCYLA treated patients.&nbsp; The most frequent adverse reactions leading to a dose delay of KADCYLA (in &ge; 1% of patients) were neutropenia, thrombocytopenia and AST increased.&nbsp;</strong></p><p dir="ltr"><strong>Selected laboratory abnormalities are shown in Table 6. The most common adverse reactions seen with KADCYLA in the randomized trial (frequency &gt; 25%) were fatigue, nausea, increased transaminases, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, peripheral neuropathy, and arthralgia.&nbsp; The most common NCI&ndash;CTCAE (version 3) Grade &ge; 3 adverse reactions (&gt; 2%) were thrombocytopenia and hypertension.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table&nbsp;5 Adverse Reactions Occurring in &ge; 10% of Patients in the KATHERINE Trial1&nbsp;</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Adverse Reactions&nbsp;</strong></p></td><td colspan="2"><p dir="ltr"><strong>KADCYLA</strong></p><p dir="ltr"><strong>n=740</strong></p></td><td colspan="2"><p dir="ltr"><strong>Trastuzumab&nbsp;</strong></p><p dir="ltr"><strong>n=720</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>All grades (%)</strong></p></td><td><p dir="ltr"><strong>Grade 3 &ndash; 4 (%)</strong></p></td><td><p dir="ltr"><strong>All grades (%)</strong></p></td><td><p dir="ltr"><strong>Grade 3 &ndash; 4 (%)</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Blood and Lymphatic System&nbsp;</strong></p><p dir="ltr"><strong>Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Thrombocytopenia</strong></p></td><td><p dir="ltr"><strong>29</strong></p></td><td><p dir="ltr"><strong>6</strong></p></td><td><p dir="ltr"><strong>2.4</strong></p></td><td><p dir="ltr"><strong>0.3</strong></p></td></tr><tr><td><p dir="ltr"><strong>Anemia</strong></p></td><td><p dir="ltr"><strong>10</strong></p></td><td><p dir="ltr"><strong>1.1</strong></p></td><td><p dir="ltr"><strong>9</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Gastrointestinal Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Nausea</strong></p></td><td><p dir="ltr"><strong>42</strong></p></td><td><p dir="ltr"><strong>0.5</strong></p></td><td><p dir="ltr"><strong>13</strong></p></td><td><p dir="ltr"><strong>0.3</strong></p></td></tr><tr><td><p dir="ltr"><strong>Constipation</strong></p></td><td><p dir="ltr"><strong>17</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td><td><p dir="ltr"><strong>8</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Stomatitis</strong></p></td><td><p dir="ltr"><strong>15</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td><td><p dir="ltr"><strong>8</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td></tr><tr><td><p dir="ltr"><strong>Vomiting</strong></p></td><td><p dir="ltr"><strong>15</strong></p></td><td><p dir="ltr"><strong>0.5</strong></p></td><td><p dir="ltr"><strong>5</strong></p></td><td><p dir="ltr"><strong>0.3</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dry Mouth</strong></p></td><td><p dir="ltr"><strong>14</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td><td><p dir="ltr"><strong>1.3</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Diarrhea</strong></p></td><td><p dir="ltr"><strong>12</strong></p></td><td><p dir="ltr"><strong>0.8</strong></p></td><td><p dir="ltr"><strong>13</strong></p></td><td><p dir="ltr"><strong>0.3</strong></p></td></tr><tr><td><p dir="ltr"><strong>Abdominal pain</strong></p></td><td><p dir="ltr"><strong>11</strong></p></td><td><p dir="ltr"><strong>0.4</strong></p></td><td><p dir="ltr"><strong>7</strong></p></td><td><p dir="ltr"><strong>0.3</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>General Disorders and&nbsp;</strong></p><p dir="ltr"><strong>Administration</strong></p></td></tr><tr><td><p dir="ltr"><strong>Fatigue</strong></p></td><td><p dir="ltr"><strong>50</strong></p></td><td><p dir="ltr"><strong>1.1</strong></p></td><td><p dir="ltr"><strong>34</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pyrexia</strong></p></td><td><p dir="ltr"><strong>10</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>4</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Infections and Infestations</strong></p></td></tr><tr><td><p dir="ltr"><strong>Urinary tract infection</strong></p></td><td><p dir="ltr"><strong>10</strong></p></td><td><p dir="ltr"><strong>0.3</strong></p></td><td><p dir="ltr"><strong>6</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Investigations</strong></p></td></tr><tr><td><p dir="ltr"><strong>Transaminases increased</strong></p></td><td><p dir="ltr"><strong>32</strong></p></td><td><p dir="ltr"><strong>1.5</strong></p></td><td><p dir="ltr"><strong>8</strong></p></td><td><p dir="ltr"><strong>0.4</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Musculoskeletal and Connective&nbsp;</strong></p><p dir="ltr"><strong>Tissue Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Musculoskeletal pain</strong></p></td><td><p dir="ltr"><strong>30</strong></p></td><td><p dir="ltr"><strong>0.7</strong></p></td><td><p dir="ltr"><strong>29</strong></p></td><td><p dir="ltr"><strong>0.7</strong></p></td></tr><tr><td><p dir="ltr"><strong>Arthralgia</strong></p></td><td><p dir="ltr"><strong>26</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td><td><p dir="ltr"><strong>21</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Myalgia</strong></p></td><td><p dir="ltr"><strong>15</strong></p></td><td><p dir="ltr"><strong>0.4</strong></p></td><td><p dir="ltr"><strong>11</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Nervous System Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Headache</strong></p></td><td><p dir="ltr"><strong>28</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>17</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td></tr><tr><td><p dir="ltr"><strong>Peripheral neuropathy</strong></p></td><td><p dir="ltr"><strong>28</strong></p></td><td><p dir="ltr"><strong>1.6</strong></p></td><td><p dir="ltr"><strong>14</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dizziness</strong></p></td><td><p dir="ltr"><strong>10</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td><td><p dir="ltr"><strong>8</strong></p></td><td><p dir="ltr"><strong>0.3</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Psychiatric Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Insomnia</strong></p></td><td><p dir="ltr"><strong>14</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>12</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Respiratory, Thoracic, and&nbsp;</strong></p><p dir="ltr"><strong>Mediastinal Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Epistaxis</strong></p></td><td><p dir="ltr"><strong>22</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>3.5</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cough</strong></p></td><td><p dir="ltr"><strong>14</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td><td><p dir="ltr"><strong>12</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td colspan="5"><p dir="ltr"><strong>Vascular Disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hemorrhage</strong></p></td><td><p dir="ltr"><strong>29</strong></p></td><td><p dir="ltr"><strong>0.4*</strong></p></td><td><p dir="ltr"><strong>10</strong></p></td><td><p dir="ltr"><strong>0.3</strong></p></td></tr></tbody></table><p>&nbsp;</p><ol><li dir="ltr"><p dir="ltr"><strong>Grouped terms were used for the following Adverse Reactions:&nbsp;</strong></p></li></ol><p dir="ltr"><strong>Thrombocytopenia: thrombocytopenia, platelet count decreased&nbsp;</strong></p><p dir="ltr"><strong>Anemia: anemia, hemoglobin decreased&nbsp;</strong></p><p dir="ltr"><strong>Stomatitis: stomatitis, mucosal inflammation, oropharyngeal pain&nbsp;</strong></p><p dir="ltr"><strong>Abdominal pain: abdominal pain, abdominal pain upper</strong></p><p dir="ltr"><strong>Urinary Tract Infection: urinary tract infection, cystitis</strong></p><p dir="ltr"><strong>Transaminases Increased: transaminases increased, aspartate aminotransferase increased, alanine aminotransferase increased, gamma-glutamyltransferase increased, liver function test abnormal, hepatic enzyme increased, hepatic function abnormal</strong></p><p dir="ltr"><strong>Musculoskeletal Pain: muscle spasms, musculoskeletal discomfort, musculoskeletal chest pain, back pain, pain in extremity, bone pain, musculoskeletal pain&nbsp;</strong></p><p dir="ltr"><strong>Peripheral neuropathy: neuropathy peripheral, peripheral sensory neuropathy, peripheral motor neuropathy, paresthesia</strong></p><p dir="ltr"><strong>Hemorrhage: Hemorrhage terms (excl laboratory terms) (SMQ, wide), Hemorrhage laboratory terms (SMQ, narrow)&nbsp;</strong></p><p dir="ltr"><strong>*Included one fatal hemorrhage.</strong></p><p dir="ltr"><strong>SMQ=standardized MedDRA queries</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The following clinically relevant adverse reactions were reported in &lt; 10% of patients in the KADCYLA-treated group in KATHERINE: blood alkaline phosphatase increased (8%), dysgeusia (8%), dyspnea (8%), neutropenia (8%), blood bilirubin increased (7%), hypokalemia (7%), pruritus (7%),&nbsp; hypertension (6%), lacrimation increased (6%), chills (5%), dry eye (4.5%), dyspepsia (4.3%), peripheral edema (3.9%),vision blurred (3.9%), conjunctivitis (3.5%), left ventricular dysfunction (3.0%), &nbsp; drug hypersensitivity (2.7%), infusion-related reaction (1.6%), radiation pneumonitis (1.5%), pneumonitis (1.1%), rash (1.1%), asthenia (0.4%), nodular regenerative hyperplasia (0.3%).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 6 Selected Laboratory Abnormalities (KATHERINE)</strong></p><table><tbody><tr><td rowspan="2"><p dir="ltr"><strong>Parameter</strong></p></td><td colspan="3"><p dir="ltr"><strong>KADCYLA</strong></p><p dir="ltr"><strong>n=740</strong></p></td><td colspan="3"><p dir="ltr"><strong>Trastuzumab&nbsp;</strong></p><p dir="ltr"><strong>n=720</strong></p></td></tr><tr><td><p dir="ltr"><strong>All Grade (%)</strong></p></td><td><p dir="ltr"><strong>Grade 3 (%)</strong></p></td><td><p dir="ltr"><strong>Grade 4 (%)</strong></p></td><td><p dir="ltr"><strong>All Grade (%)</strong></p></td><td><p dir="ltr"><strong>Grade 3 (%)</strong></p></td><td><p dir="ltr"><strong>Grade 4 (%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Chemistry</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Increased AST</strong></p></td><td><p dir="ltr"><strong>79</strong></p></td><td><p dir="ltr"><strong>0.8</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>21</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Increased ALT</strong></p></td><td><p dir="ltr"><strong>55</strong></p></td><td><p dir="ltr"><strong>0.7</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>21</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Decreased potassium</strong></p></td><td><p dir="ltr"><strong>26</strong></p></td><td><p dir="ltr"><strong>2</strong></p></td><td><p dir="ltr"><strong>0.5</strong></p></td><td><p dir="ltr"><strong>9</strong></p></td><td><p dir="ltr"><strong>0.7</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td></tr><tr><td><p dir="ltr"><strong>Increased bilirubin</strong></p></td><td><p dir="ltr"><strong>12</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>4</strong></p></td><td><p dir="ltr"><strong>0.7</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hematology</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Decreased platelet count</strong></p></td><td><p dir="ltr"><strong>51</strong></p></td><td><p dir="ltr"><strong>4</strong></p></td><td><p dir="ltr"><strong>2</strong></p></td><td><p dir="ltr"><strong>13</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td><td><p dir="ltr"><strong>0.1</strong></p></td></tr><tr><td><p dir="ltr"><strong>Decreased hemoglobin</strong></p></td><td><p dir="ltr"><strong>31</strong></p></td><td><p dir="ltr"><strong>1</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>29</strong></p></td><td><p dir="ltr"><strong>0.3</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Decreased neutrophils</strong></p></td><td><p dir="ltr"><strong>24</strong></p></td><td><p dir="ltr"><strong>1</strong></p></td><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>19</strong></p></td><td><p dir="ltr"><strong>0.6</strong></p></td><td><p dir="ltr"><strong>0.6</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>Immunogenicity</strong></p><p dir="ltr"><strong>As with all therapeutic proteins, there is the potential for an immune response to KADCYLA. A total of 1243 patients from seven clinical studies were tested at multiple time points for anti-drug antibody (ADA) responses to KADCYLA.&nbsp; Following KADCYLA dosing, 5.1% (63/1243) of patients tested positive for anti-KADCYLA antibodies at one or more post-dose time points.&nbsp; In clinical studies, 6.4% (24/376) of patients tested positive for anti-KADCYLA antibodies.&nbsp; In EMILIA, 5.2% (24/466) of patients tested positive for anti-KADCYLA antibodies, of which 13 were also positive for neutralizing antibodies.&nbsp; In KATHERINE, 3.7% (15/401) of patients tested positive for anti-KADCYLA antibodies, of which 5 were also positive for neutralizing antibodies.&nbsp; Due to the low incidence of ADA, conclusions cannot be made on the impact of anti-KADCYLA antibodies on the pharmacokinetics, safety, and efficacy of KADCYLA. The presence of KADCYLA in patient serum at the time of ADA sampling may interfere with the ability of this assay to detect anti-KADCYLA antibodies.&nbsp; As a result, data may not accurately reflect the true incidence of anti-KADCYLA antibody development.&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>Immunogenicity data are highly dependent on the sensitivity and specificity of the test methods used.&nbsp; Additionally, the observed incidence of a positive result in a test method may be influenced by several factors, including sample handling, timing of sample collection, drug interference, concomitant medication and the underlying disease.&nbsp; Therefore, comparison of the incidence of antibodies to KADCYLA with the incidence of antibodies to other products may be misleading.&nbsp; Clinical significance of anti-KADCYLA antibodies is not yet known.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Post-Marketing Experience</strong></p><p dir="ltr"><strong>The following adverse reactions have been identified during post-approval use of KADCYLA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>Tumor lysis syndrome (TLS): Cases of possible TLS have been reported in patients treated with KADCYLA. Patients with significant tumor burden (e.g., bulky metastases) may be at a higher risk. Patients could present with hyperuricemia, hyperphosphatemia, and acute renal failure which may represent possible TLS.&nbsp;&nbsp;Providers should consider additional monitoring and/or treatment as clinically indicated.</strong></p></li></ul><p>&nbsp;</p><p dir="ltr"><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><ul><li dir="ltr"><p dir="ltr"><strong>Saudi Arabia:</strong></p></li></ul><p>&nbsp;</p><p dir="ltr"><strong><img width="550" height="140" src="https://docs.google.com/drawings/u/0/d/sDszr38Q8qpQdk8P4OgiMCg/image?w=550&amp;h=140&amp;rev=1&amp;ac=1&amp;parent=1I6wTFOEYOUumsxM6djG5N7ImepAFIGCE" /></strong></p><p>&nbsp;</p><ul><li dir="ltr"><p dir="ltr"><strong>Other GCC States:</strong></p></li></ul><p dir="ltr"><strong><img width="550" height="37" src="https://docs.google.com/drawings/u/0/d/sDPjKaX8QnxqmxDOLu2HVgw/image?w=550&amp;h=37&amp;rev=1&amp;ac=1&amp;parent=1I6wTFOEYOUumsxM6djG5N7ImepAFIGCE" /></strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>There is no known antidote for overdose of KADCYLA.&nbsp; In clinical trials, overdose of KADCYLA has been reported at approximately two times the recommended dose which resulted in Grade 2 thrombocytopenia (resolved 4 days later) and one death.&nbsp; In the fatal case, the patient incorrectly received KADCYLA at 6 mg/kg and died approximately 3 weeks following the overdose; a cause of death and a causal relationship to KADCYLA were not established.</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Pharmacotherapeutic group: Antineoplastic agent, other antineoplastic agents, monoclonal</strong></p><p dir="ltr"><strong>antibodies, ATC code: L01XC14</strong></p><p>&nbsp;</p><p><strong>Mechanism of Action</strong></p><p dir="ltr"><strong>Ado-trastuzumab emtansine is a HER2-targeted antibody-drug conjugate. The antibody is the humanized anti-HER2 IgG1, trastuzumab.&nbsp; The small molecule cytotoxin, DM1, is a microtubule inhibitor. Upon binding to sub-domain IV of the HER2 receptor, ado-trastuzumab emtansine undergoes receptor-mediated internalization and subsequent lysosomal degradation, resulting in intracellular release of DM1-containing cytotoxic catabolites. Binding of DM1 to tubulin disrupts microtubule networks in the cell, which results in cell cycle arrest and apoptotic cell death.&nbsp; In addition, in vitro studies have shown that similar to trastuzumab, ado-trastuzumab emtansine inhibits HER2 receptor signaling, mediates antibody-dependent cell-mediated cytotoxicity and inhibits shedding of the HER2 extracellular domain in human breast cancer cells that overexpress HER2.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Cardiac Electrophysiology</strong></p><p dir="ltr"><strong>The effect of multiple doses of KADCYLA (3.6 mg/kg every 3 weeks) on the QTc interval was evaluated in an open label, single arm study in 51 patients with HER2-positive metastatic breast cancer.&nbsp; No large changes in the mean QT interval (i.e., &gt; 20 ms) were detected in the study.</strong></p><p>&nbsp;</p><p><strong>Clinical efficacy and safety (Clinical studies)</strong></p><p>&nbsp;</p><p><strong>Metastatic Breast Cancer</strong></p><p dir="ltr"><strong>The efficacy of KADCYLA was evaluated in a randomized, multicenter, open-label trial (EMILIA) (NCT00829166) of 991 patients with HER2-positive, unresectable locally advanced or metastatic breast cancer. Prior taxane and trastuzumab-based therapy was required before trial enrollment.&nbsp; Patients with only prior adjuvant therapy were required to have disease recurrence during or within six months of completing adjuvant therapy.&nbsp; Breast tumor samples were required to show HER2 overexpression defined as 3+ IHC or FISH amplification ratio &ge; 2.0 determined at a central laboratory.&nbsp; Patients were randomly allocated (1:1) to receive lapatinib plus capecitabine or KADCYLA.&nbsp; Randomization was stratified by world region (United States, Western Europe, other), number of prior chemotherapy regimens for unresectable locally advanced or metastatic disease (0&ndash;1, &gt; 1) and visceral versus non-visceral disease as determined by the investigators.&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>KADCYLA was given intravenously at 3.6 mg/kg on Day 1 of a 21-day cycle.&nbsp; Lapatinib was administered at 1250 mg/day orally once per day of a 21-day cycle and capecitabine was administered at 1000 mg/m2 orally twice daily on Days 1&minus;14 of a 21-day cycle.&nbsp; Patients were treated with KADCYLA or lapatinib plus capecitabine until progression of disease, withdrawal of consent, or unacceptable toxicity.&nbsp; At the time of the primary analysis, median time on study drug was 5.7 months (range: 0&minus;28.4) for KADCYLA, 4.9 months (range: 0&minus;30.8) for lapatinib, and 4.8 months (range: 0&minus;30.4) for capecitabine.</strong></p><p dir="ltr"><strong>The co-primary efficacy outcomes of the study were progression-free survival (PFS) based on tumor response assessments by an independent review committee (IRC), and overall survival (OS).&nbsp; PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause (whichever occurred earlier).&nbsp; Overall survival was defined as the time from the date of randomization to the date of death from any cause.&nbsp; Additional outcomes included PFS (based on investigator tumor response assessments), objective response rate (ORR), duration of response and time to symptom progression.&nbsp;</strong></p><p dir="ltr"><strong>Patient demographics and baseline tumor characteristics were balanced between treatment arms. All patients had metastatic disease at study entry.&nbsp; The median age was approximately 53 years (range 24-84 years), 74% were White, 18% were Asian and 5% were Black.&nbsp; All but 5 patients were women.&nbsp; Twenty-seven percent of patients were enrolled in United States, 32% in Europe and 16% in Asia.&nbsp; Tumor prognostic characteristics including hormone receptor status (positive: 55%, negative: 43%), presence of visceral disease (68%) and non-visceral disease only (33%) and the number of metastatic sites (&lt; 3: 61%, &ge; 3: 37%) were similar in the study arms.&nbsp;&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>The majority of patients (88%) had received prior systemic treatment in the metastatic setting.&nbsp; Twelve percent of patients had prior treatment only in the neoadjuvant or adjuvant setting and had disease relapse within 6 months of treatment.&nbsp; All but one patient received trastuzumab prior to study entry; approximately 85% of patients received prior trastuzumab in the metastatic setting.&nbsp; Over 99% percent of patients had received a taxane, and 61% of patients had received an anthracycline prior to study entry.&nbsp; Overall, patients received a median of 3&nbsp;systemic agents in the metastatic setting. Among patients with hormone receptor-positive tumors, 44.4% received prior adjuvant hormonal therapy and 44.8% received hormonal therapy for locally advanced/metastatic disease.</strong></p><p dir="ltr"><strong>The randomized trial demonstrated a statistically significant improvement in IRC-assessed PFS in the KADCYLA-treated group compared with the lapatinib plus capecitabine-treated group [hazard ratio (HR) = 0.65, 95% CI: 0.55, 0.77, p &lt; 0.0001], and an increase in median PFS of 3.2 months (median PFS of 9.6 months in the KADCYLA-treated group vs. 6.4 months in the lapatinib plus capecitabine group).&nbsp; See Table 7 and Figure 1.&nbsp; The results for investigator-assessed PFS were similar to those observed for IRC-assessed PFS.&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>At the time of PFS analysis, 223 patients had died.&nbsp; More deaths occurred in the lapatinib plus capecitabine arm (26%) compared with the KADCYLA arm (19%), however the results of this interim OS analysis did not meet the pre-specified stopping boundary for statistical significance. At the time of the second interim OS analysis, 331 events had occurred.&nbsp; The co-primary endpoint of OS was met; OS was significantly improved in patients receiving KADCYLA (HR = 0.68, 95% CI: 0.55, 0.85, p = 0.0006).&nbsp; This result crossed the pre-specified efficacy stopping boundary (HR = 0.73 or p = 0.0037).&nbsp; The median duration of survival was 30.9 months in the KADCYLA arm vs. 25.1 months in the lapatinib plus capecitabine arm.&nbsp; See Table 7 and Figure 2.</strong></p><p dir="ltr"><strong>A treatment benefit with KADCYLA in terms of PFS and OS was observed in patient subgroups based on stratification factors, key baseline demographic and disease characteristics, and prior treatments.&nbsp; In the subgroup of patients with hormone receptor-negative disease (n=426), the hazard ratios for PFS and OS were 0.56 (95% CI: 0.44, 0.72) and 0.75 (95% CI: 0.54, 1.03), respectively.&nbsp; In the subgroup of patients with hormone receptor-positive disease (n=545), the hazard ratios for PFS and OS were 0.72 (95% CI: 0.58, 0.91) and 0.62 (95% CI: 0.46, 0.85), respectively.&nbsp; In the subgroup of patients with non-measurable disease (n=205), based on IRC assessments, the hazard ratios for PFS and OS were 0.91 (95% CI: 0.59, 1.42) and 0.96 (95% CI: 0.54, 1.68), respectively; in patients with measurable disease the hazard ratios were 0.62 (95% CI: 0.52, 0.75) and 0.65 (95% CI: 0.51, 0.82), respectively.&nbsp; The PFS and OS hazard ratios in patients who were younger than 65 years old (n=853) were 0.62 (95% CI: 0.52, 0.74) and 0.66 (95% CI: 0.52, 0.83), respectively.&nbsp; In patients &ge; 65 years old (n=138), the hazard ratios for PFS and OS were 1.06 (95% CI: 0.68, 1.66) and 1.05 (95% CI: 0.58, 1.91), respectively.</strong></p><p><br />&nbsp;</p><p dir="ltr"><strong>Table&nbsp;7 Summary of Efficacy from EMILIA</strong></p><table><tbody><tr><td>&nbsp;</td><td><p dir="ltr"><strong>KADCYLA</strong></p><p dir="ltr"><strong>N=495</strong></p></td><td><p dir="ltr"><strong>Lapatinib+Capecitabine</strong></p><p dir="ltr"><strong>N=496</strong></p></td></tr><tr><td><p dir="ltr"><strong>Progression-Free Survival</strong></p><p dir="ltr"><strong>(independent review)&nbsp;</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>&nbsp; Number (%) of patients with event&nbsp;</strong></p></td><td><p dir="ltr"><strong>265 (53.5%)</strong></p></td><td><p dir="ltr"><strong>304 (61.3%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>&nbsp; Median duration of PFS (months)&nbsp;</strong></p></td><td><p dir="ltr"><strong>9.6</strong></p></td><td><p dir="ltr"><strong>6.4</strong></p></td></tr><tr><td><p dir="ltr"><strong>&nbsp; Hazard Ratio (stratified*)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.650</strong></p></td></tr><tr><td><p dir="ltr"><strong>&nbsp; 95% CI for Hazard Ratio</strong></p></td><td colspan="2"><p dir="ltr"><strong>(0.549, 0.771)</strong></p></td></tr><tr><td><p dir="ltr"><strong>&nbsp; p-value (Log-Rank test, stratified*)</strong></p></td><td colspan="2"><p dir="ltr"><strong>&lt; 0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>Overall Survival &dagger;</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>&nbsp; Number (%) of patients who died&nbsp;</strong></p></td><td><p dir="ltr"><strong>149 (30.1%)</strong></p></td><td><p dir="ltr"><strong>182 (36.7%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>&nbsp; Median duration of survival (months)</strong></p></td><td><p dir="ltr"><strong>30.9</strong></p></td><td><p dir="ltr"><strong>25.1</strong></p></td></tr><tr><td><p dir="ltr"><strong>&nbsp; Hazard Ratio (stratified*)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.682</strong></p></td></tr><tr><td><p dir="ltr"><strong>&nbsp; 95% CI for Hazard Ratio</strong></p></td><td colspan="2"><p dir="ltr"><strong>(0.548, 0.849)</strong></p></td></tr><tr><td><p dir="ltr"><strong>&nbsp; p-value (Log-Rank test*)</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.0006</strong></p></td></tr><tr><td><p dir="ltr"><strong>Objective Response Rate</strong></p></td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>(independent review)&nbsp;</strong></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>&nbsp; Patients with measurable disease</strong></p></td><td><p dir="ltr"><strong>397</strong></p></td><td><p dir="ltr"><strong>389</strong></p></td></tr><tr><td><p dir="ltr"><strong>Number of patients with OR (%)</strong></p></td><td><p dir="ltr"><strong>173 (43.6%)</strong></p></td><td><p dir="ltr"><strong>120 (30.8%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Difference (95% CI)</strong></p></td><td colspan="2"><p dir="ltr"><strong>12.7% (6.0, 19.4)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Duration of Objective Response (months)</strong></p><p dir="ltr"><strong>&nbsp;&nbsp;Number of patients with OR</strong></p></td><td>&nbsp;<p dir="ltr"><strong>173</strong></p></td><td>&nbsp;<p dir="ltr"><strong>120</strong></p></td></tr><tr><td><p dir="ltr"><strong>&nbsp; Median duration (95% CI)</strong></p></td><td colspan="2"><p dir="ltr"><strong>12.6 (8.4, 20.8) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6.5 (5.5, 7.2)</strong></p></td></tr><tr><td colspan="3"><p dir="ltr"><strong>PFS: progression-free survival; OR: objective response</strong></p><p dir="ltr"><strong>* Stratified by world region (United States, Western Europe, other), number of prior chemotherapeutic regimens for locally advanced or metastatic disease (0-1 vs. &gt; 1), and visceral vs. non-visceral disease.</strong></p><p dir="ltr"><strong>&dagger; The second interim analysis for OS was conducted when 331 events were observed and the results are presented in this table.</strong></p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure 1 Kaplan-Meier Curve of IRC-Assessed Progression-Free Survival for EMILIA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p><p dir="ltr"><strong><img width="624" height="373" src="https://lh6.googleusercontent.com/Yu4z1Hd_mRaxE5JUY8TvzOGNzbbcwsuu7hUaZiXlrl07rtO3HE7HLZ8e791wnBElfLkTWic4Um-OG-4s1Vi9J0TZtFlfyY_dEiawGT59Tw3ZhJuCtUQWEwTG9LedgusITFjqM6U" /></strong></p><p><br /><br />&nbsp;</p><p dir="ltr"><strong>Figure&nbsp;2 Kaplan-Meier Curve of Overall Survival for EMILIA<img width="624" height="395" src="https://lh3.googleusercontent.com/f-dmqNDYp8rBQjZb5w5W3EREWCPkFu7b_obKr2hQzi2ZNy80AQFkEwXEAc4OVgMecjA3-CS3qmmjWSblMp_CyVMBkskwnJuXuFV5OwH69OG9OA6CRd-95vj6VpNO3VE2Byy1m8w" /></strong></p><p>&nbsp;</p><p><strong>Early Breast Cancer</strong></p><p>&nbsp;</p><p dir="ltr"><strong>KATHERINE (NCT01772472) was a randomized, multicenter, open-label trial of 1486 patients with HER2-positive, early breast cancer. Patients were required to have had neoadjuvant taxane and trastuzumab-based therapy with residual invasive tumor in the breast and/or axillary lymph nodes. Patients received radiotherapy and/or hormonal therapy concurrent with study treatment as per local guidelines. Breast tumor samples were required to show HER2 overexpression defined as 3+ IHC or ISH amplification ratio &ge; 2.0 determined at a central laboratory using Ventana&rsquo;s PATHWAY anti-HER2-/neu (4B5) Rabbit Monoclonal Primary Antibody or INFORM HER2 Dual ISH DNA Probe Cocktail assays.&nbsp; Patients were randomized (1:1) to receive KADCYLA or trastuzumab.&nbsp; Randomization was stratified by clinical stage at presentation, hormone receptor status, preoperative HER2-directed therapy (trastuzumab, trastuzumab plus additional HER2-directed agent[s]), and pathological nodal status evaluation after preoperative therapy.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>KADCYLA was given intravenously at 3.6 mg/kg on Day 1 of a 21-day cycle.&nbsp; Trastuzumab was given intravenously at 6 mg/kg on Day 1 of a 21-day cycle. Patients were treated with KADCYLA or trastuzumab for a total of 14 cycles unless there was recurrence of disease, withdrawal of consent, or unacceptable toxicity.&nbsp; At the time of the major efficacy outcome analysis, median treatment duration was 10 months for both KADCYLA- and trastuzumab-treated patients. Patients who discontinued KADCYLA for reasons other than disease recurrence could complete the remainder of the planned HER2-directed therapy with trastuzumab if appropriate based on toxicity considerations and investigator discretion.</strong></p><p dir="ltr"><strong>The major efficacy outcome of the study was invasive disease-free survival (IDFS). IDFS was defined as the time from the date of randomization to first occurrence of ipsilateral invasive breast tumor recurrence, ipsilateral local or regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, or death from any cause.&nbsp; Additional efficacy outcomes included IDFS including second primary non-breast cancer, disease free survival (DFS), and overall survival (OS).</strong></p><p dir="ltr"><strong>Patient demographics and baseline tumor characteristics were generally balanced between treatment arms.&nbsp; The median age was approximately 49 years (range 23-80 years), 73% were White, 9% were Asian, 6% were American Indian or Alaska Native and 3% were Black or African American.&nbsp; Most patients (99.7%) were women. Enrollment by region was as follows: 23% in North America, 54% in Europe and 23% throughout the rest of the world.&nbsp; Tumor prognostic characteristics including hormone receptor status (positive: 72%, negative: 28%), clinical stage at presentation (inoperable: 25%, operable: 75%) and pathological nodal status after preoperative therapy (node positive: 46%, node negative or not evaluated: 54%) were similar across study arms.&nbsp;&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>The majority of patients (77%) had received an anthracycline-containing neoadjuvant chemotherapy regimen. Twenty percent of patients received another HER2-targeted agent in addition to trastuzumab as a component of neoadjuvant therapy; 94% of these patients received pertuzumab.&nbsp;</strong></p><p dir="ltr"><strong>After a median follow-up of 40 months, a statistically significant improvement in IDFS was observed in patients who received KADCYLA compared with trastuzumab. The OS data were not mature at the time of the IDFS analysis (98 deaths [6.6%] occurred in 1486 patients). The efficacy results from KATHERINE are summarized in Table 8 and Figure 3.</strong></p><p dir="ltr"><strong>Consistent results were observed with KADCYLA in terms of IDFS across subgroups based on stratification factors, key baseline demographic and disease characteristics, and prior treatments.&nbsp;</strong></p><p dir="ltr"><strong>Table&nbsp;8 Efficacy Results from KATHERINE&nbsp;</strong></p><table><tbody><tr><td>&nbsp;</td><td><p dir="ltr"><strong>KADCYLA&nbsp;</strong></p><p dir="ltr"><strong>N=743</strong></p></td><td><p dir="ltr"><strong>Trastuzumab&nbsp;</strong></p><p dir="ltr"><strong>N=743</strong></p></td></tr><tr><td><p dir="ltr"><strong>Invasive Disease-Free Survival (IDFS)1,4&nbsp;</strong></p></td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Number (%) of patients with event&nbsp;</strong></p></td><td><p dir="ltr"><strong>91 (12.2%)</strong></p></td><td><p dir="ltr"><strong>165 (22.2%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>HR [95% CI]2</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.50 [0.39, 0.64]</strong></p></td></tr><tr><td><p dir="ltr"><strong>p-value (Log-Rank test, unstratified)</strong></p></td><td colspan="2"><p dir="ltr"><strong>&lt; 0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>3-year event-free rate3, % [95% CI]&nbsp;</strong></p></td><td><p dir="ltr"><strong>88.3 [85.8, 90.7]</strong></p></td><td><p dir="ltr"><strong>77.0 [73.8, 80.7]</strong></p></td></tr><tr><td><p dir="ltr"><strong>IDFS including second primary non-breast cancer</strong></p></td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Number (%) of patients with event&nbsp;</strong></p></td><td><p dir="ltr"><strong>95 (12.8%)</strong></p></td><td><p dir="ltr"><strong>167 (22.5%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>HR [95% CI]2</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.51 [0.40, 0.66]</strong></p></td></tr><tr><td><p dir="ltr"><strong>3-year event-free rate3, % [95% CI]&nbsp;</strong></p></td><td><p dir="ltr"><strong>87.7 [85.2, 90.2]</strong></p></td><td><p dir="ltr"><strong>76.9 [73.7, 80.1]</strong></p></td></tr><tr><td><p dir="ltr"><strong>Disease-Free Survival (DFS)&nbsp;</strong></p></td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Number (%) of patients with event</strong></p></td><td><p dir="ltr"><strong>98 (13.2%)</strong></p></td><td><p dir="ltr"><strong>167 (22.5%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>HR [95% CI]2</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.53 [0.41, 0.68]</strong></p></td></tr><tr><td><p dir="ltr"><strong>3-year event-free rate3, % [95% CI]</strong></p></td><td><p dir="ltr"><strong>87.4 [84.9, 89.9]</strong></p></td><td><p dir="ltr"><strong>76.9 [73.7, 80.1]</strong></p></td></tr></tbody></table><p dir="ltr"><strong>HR: Hazard Ratio; CI: Confidence Intervals,&nbsp;</strong></p><p dir="ltr"><strong>1 Hierarchical testing applied for IDFS and OS</strong></p><p dir="ltr"><strong>2 Unstratified analysis</strong></p><p dir="ltr"><strong>3 3-year event-free rate derived from Kaplan-Meier estimates</strong></p><p dir="ltr"><strong>4 Data from the pre-specified interim analysis (67% of the number of events for the planned final analysis) with the p-value compared with the allocated alpha of 0.012</strong></p><p><br /><br />&nbsp;</p><p dir="ltr"><strong>Figure&nbsp;3 Kaplan-Meier Curve of Invasive Disease-Free Survival in KATHERINE<img width="624" height="330" src="https://lh5.googleusercontent.com/c4bqfS3m7t-dI6cw_cjWpUM5oaOz8h3u9IMf5A86yEJzrIF2aUEx50Z9aj0tzlPGiOq4mXfRB6l-_U3cj0ED45knf82VMznPXXcYM2TWeyV4-CinKYNkzc29BOZKmEY18QErvO0" /></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>The pharmacokinetics of KADCYLA was evaluated in a phase 1 study and in a population pharmacokinetic analysis for the ado-trastuzumab emtansine conjugate (ADC) using pooled data from 5 trials in patients with breast cancer.&nbsp; A linear two-compartment model with first-order elimination from the central compartment adequately describes the ADC concentration-time profile. In addition to ADC, the pharmacokinetics of total antibody (conjugated and unconjugated trastuzumab), DM1 were also determined.&nbsp; The population pharmacokinetic analysis of ADC suggested no difference in KADCYLA exposure based on disease status (adjuvant vs. metastatic setting). The pharmacokinetics of KADCYLA are summarized below.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Distribution</strong></p><p dir="ltr"><strong>Maximum concentrations (Cmax) of ADC and DM1 were observed close to the end of infusion. In EMILIA, mean (SD) ADC and DM1 Cycle 1 Cmax following KADCYLA administration was 83.4 (16.5) g/mL and 4.61 (1.61) ng/mL, respectively. In KATHERINE, mean (SD) ADC and DM1 Cycle 1 Cmax following KADCYLA administration was 72.6 (24.3) g/mL and 4.71 (2.25) ng/mL, respectively.</strong></p><p dir="ltr"><strong>In vitro, the mean binding of DM1 to human plasma proteins was 93%. In vitro, DM1 was a substrate of P-glycoprotein (P-gp).</strong></p><p dir="ltr"><strong>Based on population pharmacokinetic analysis, the central volume of distribution of ADC was 3.13 L.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Metabolism</strong></p><p dir="ltr"><strong>In vitro studies indicate that DM1, the small molecule component of KADCYLA, undergoes metabolism by CYP3A4/5.&nbsp; DM1 did not inhibit or induce major CYP450 enzymes in vitro.&nbsp; In human plasma, ado-trastuzumab emtansine catabolites MCC-DM1, Lys-MCC-DM1, and DM1 were detected at low levels.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elimination</strong></p><p dir="ltr"><strong>Based on population pharmacokinetic analysis, following intravenous infusion of KADCYLA, the clearance of the ADC was 0.68 L/day and the elimination half-life (t1/2) was approximately 4 days. No accumulation of KADCYLA was observed after repeated dosing of intravenous infusion every 3 weeks.</strong></p><p dir="ltr"><strong>Based on population pharmacokinetic analysis (n=671), body weight, sum of longest diameter of target lesions by RECIST, HER2 extracellular domain (ECD) concentrations, AST, albumin, and baseline trastuzumab concentrations were identified as statistically significant covariates for ado-trastuzumab emtansine clearance.&nbsp; However, the magnitude of effect of these covariates on ado-trastuzumab emtansine exposure suggests that, with the exception of body weight, these covariates are unlikely to have a clinically meaningful effect on KADCYLA exposure.&nbsp; Therefore, the body weight based dose of 3.6 mg/kg every 3 weeks without correction for other covariates is considered appropriate.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Effect of Renal Impairment</strong></p><p dir="ltr"><strong>Based on population pharmacokinetic analysis in 668 patients, including moderate (CLcr 30 - 59 mL/min, n=53) and mild (CLcr 60 - 89 mL/min, n=254) renal impairment, indicate that pharmacokinetics of the ADC is not affected by mild to moderate renal impairment as compared to normal renal function (CLcr &ge; 90 mL/min, n=361).&nbsp; Data from only one patient with severe renal impairment (CLcr &lt; 30 mL/min) is available [see Fertility, pregnancy and lactation (4.6)].</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Effect of Hepatic Impairment</strong></p><p dir="ltr"><strong>The liver is a primary organ for eliminating DM1 and DM1-containing catabolites.&nbsp; The pharmacokinetics of ado-trastuzumab emtansine and DM1-containing catabolites were evaluated after the administration of 3.6 mg/kg of KADCYLA to metastatic HER2-positive breast cancer patients with normal hepatic function (n=10), mild (Child-Pugh A; n=10) and moderate (Child-Pugh B; n=8) hepatic impairment.</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>Plasma concentrations of DM1 and DM1-containing catabolites (Lys-MCC-DM1 and MCC-DM1) were low and comparable between patients with and without hepatic impairment.&nbsp;</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Systemic exposures (AUC) of ado-trastuzumab emtansine at Cycle 1 in patients with mild and moderate hepatic impairment were approximately 38% and 67% lower than that of patients with normal hepatic function, respectively.&nbsp; Ado-trastuzumab emtansine exposure (AUC) at Cycle 3 after repeated dosing in patients with mild or moderate hepatic dysfunction was within the range observed in patients with normal hepatic function.&nbsp;</strong></p></li></ul><p dir="ltr"><strong>KADCYLA has not been studied in patients with severe hepatic impairment (Child-Pugh class C).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Effects of Age and Race&nbsp;</strong></p><p dir="ltr"><strong>Based on population pharmacokinetic analysis, age (&lt; 65 [n=577]; 65 - 75 (n=78); &gt; 75 [n=16]) and race (Asian [n=73]; non-Asian [n=598]) do not have a clinically meaningful effect on the pharmacokinetics of ado-trastuzumab emtansine.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><br /></p><p><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility</strong></p><p dir="ltr"><strong>Carcinogenicity studies have not been conducted with ado-trastuzumab emtansine.</strong></p><p dir="ltr"><strong>DM1 was aneugenic or clastogenic in an in vivo single-dose rat bone marrow micronucleus assay at exposures that were comparable to mean maximum concentrations of DM1 measured in humans administered KADCYLA.&nbsp; DM1 was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay.&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>Based on results from animal toxicity studies, KADCYLA may impair fertility in humans.&nbsp; In a single-dose toxicity study of ado-trastuzumab emtansine in rats, degeneration of seminiferous tubules with hemorrhage in the testes associated with increased weights of testes and epididymides at a severely toxic dose level (60 mg/kg; about 4 times the clinical exposure based on AUC) were observed.&nbsp; The same dose in female rats resulted in signs of hemorrhage and necrosis of the corpus luteum in ovaries.&nbsp; In monkeys dosed with ado-trastuzumab emtansine once every three weeks for 12 weeks (four doses), at up to 30 mg/kg (about 7 times the clinical exposure based on AUC), there were decreases in the weights of epididymides, prostate, testes, seminal vesicles and uterus, although the interpretation of these effects is unclear due to the varied sexual maturity of enrolled animals.&nbsp;</strong></p><p>&nbsp;</p><p><strong>Animal Toxicology and/or Pharmacology</strong></p><p dir="ltr"><strong>In monkeys, treatment with doses of ado-trastuzumab emtansine up to 30 mg/kg (about 7 times the clinical exposure based on AUC) caused dose dependent axonal degeneration in the sciatic nerve with hypertrophy or hyperplasia of the Schwann cells, and axonal degeneration of the dorsal funiculus in the spinal cord.&nbsp; Based on the mechanism of action of the cytotoxic component DM1, there is clinical potential for neurotoxicity [see Special warnings and precautions for use (4.4)].</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Succinic acid</strong></p><p dir="ltr"><strong>Sodium hydroxide</strong></p><p dir="ltr"><strong>Sucrose</strong></p><p dir="ltr"><strong>Polysorbate&nbsp;20</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>This medicinal product must not be mixed or diluted with other medicinal products except those mentioned in section&nbsp;6.6.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Glucose&nbsp;(5%) solution should not be used for reconstitution or dilution since it causes aggregation of the protein</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

Shelf-life of the reconstituted solution 
Chemical and physical in-use stability of the reconstituted solution has been demonstrated for up to 24 hours at 2°C to 8°C. From a microbiological point of view, the product should be used immediately. If not used immediately, the reconstituted vials can be stored for up to 24 hours at 2°C to 8°C, provided it was reconstituted under controlled and validated aseptic conditions, and must be discarded thereafter.

Shelf-life of the diluted solution 
The reconstituted Kadcyla solution diluted in infusion bags containing sodium chloride 9 mg/ml (0.9%) solution for infusion, or sodium chloride 4.5 mg/ml (0.45%) solution for infusion, is stable for up to 24 hours at 2°C to 8°C, provided it was prepared under controlled and validated aseptic conditions. Particulates may be observed on storage if diluted in 0.9% sodium chloride (see section 6.6).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For storage conditions after reconstitution and dilution of the medicinal product, see section&nbsp;6.3.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Kadcyla is provided in 15&nbsp;ml (100 mg) or 20&nbsp;ml (160 mg) Type 1 glass vial closed with a grey-butyl rubber stopper coated with fluoro-resin laminate, and sealed with an aluminium seal with a white or purple plastic flip-off cap.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pack of 1&nbsp;vial.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Appropriate aseptic technique should be used. Appropriate procedures for the preparation of chemotherapeutic medicinal products should be used.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The reconstituted Kadcyla solution should be diluted in polyvinyl chloride (PVC) or latex-free PVC-free polyolefin infusion bags.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The use of 0.20 or 0.22 micron in-line polyethersulfone (PES) filter is required for the infusion when the concentrate for infusion is diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In order to prevent medication errors, it is important to check the vial labels to ensure that the medicinal product being prepared is Kadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Instructions for reconstitution</strong></p><p dir="ltr"><strong>∙ 100 mg trastuzumab emtansine vial: Using a sterile syringe, slowly inject 5&nbsp;mL of sterile water for injection into the vial.&nbsp;</strong></p><p dir="ltr"><strong>∙ 160 mg trastuzumab emtansine vial: Using a sterile syringe, slowly inject 8&nbsp;mL of sterile water for injection into the vial.&nbsp;</strong></p><p dir="ltr"><strong>∙ Swirl the vial gently until completely dissolved. Do not shake.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reconstituted solution should be inspected visually for particulate matter and discolouration prior to administration. The reconstituted solution should be free of visible particulates, clear to slightly opalescent. The colour of the reconstituted solution should be colourless to pale brown. Do not use if the reconstituted solution contains visible particulates, or is cloudy or discoloured.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Instructions for dilution</strong></p><p dir="ltr"><strong>Determine the volume of the reconstituted solution required based on a dose of 3.6&nbsp;mg trastuzumab emtansine/kg body weight (see section&nbsp;4.2):</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Volume (mL)&nbsp;=&nbsp;Total dose to be administered (body weight (kg) x dose (mg/kg))&nbsp;</strong></p><p dir="ltr"><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 20 (mg/mL, concentration of reconstituted solution)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The appropriate amount of solution should be withdrawn from the vial and added to an infusion bag containing 250&nbsp;mL of sodium chloride 4.5 mg/ml (0.45%) solution for infusion or sodium chloride 9&nbsp;mg/ml (0.9%) solution for infusion. Glucose&nbsp;(5%) solution should not be used (see section&nbsp;6.2). Sodium chloride 4.5 mg/ml (0.45%) solution for infusion may be used without a polyethersulfone (PES) 0.20 or 0.22-&mu;m in-line filter. If sodium chloride 9 mg/ml (0.9%) solution for infusion is used for infusion, a 0.20 or 0.22 micron in-line polyethersulfone (PES) filter is required. Once the infusion is prepared it should be administered immediately. Do not freeze or shake the infusion during storage.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Disposal</strong></p><p dir="ltr"><strong>The reconstituted product contains no preservative and is intended for single use only. Discard any unused portion.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                F. Hoffmann-La Roche Ltd,
Grenzacherstrasse 124,
CH-4070 Basel,
Switzerland.
8.	MARKETING AUTHORISATION NUMBER(S) 

279-24-15
280-24-15

9.	DATE OF FIRST AUTHORISATION/DATE OF LATEST RENEWAL 

Date of first authorisation: 13 June 2016.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03 May 2019

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>